Kids_First_Biospecimen_ID_DNA	Kids_First_Biospecimen_ID_RNA	Kids_First_Participant_ID	MYCN_TPM	MYCN_CN	MYCN_CN_status	sample_id	cohort	match_id	pathology_free_text_diagnosis	molecular_subtype
NA	MARIS_HEMEDKRG	Maris_P0001	2.11	NA	NA	SH-SY5Y	Maris	Maris_P0001_SH-SY5Y_Derived Cell Line_Progressive_NA_NA	1p36 del None; 3p26 del None; 11q23 del Loss q22.1-q24.2; 17q21-qter unbal gain Gain q21.31-qter; MYCN Non-amplified; ALK F1174L; TP53 WT	NBL, MYCN non-amplified
NA	MARIS_M10LINIO	Maris_P0001	6.99	NA	NA	SK-N-SH	Maris	Maris_P0001_SK-N-SH_Derived Cell Line_Progressive_NA_NA	1p36 del None; 3p26 del None; 11q23 del LOH 23.1; 17q21-qter unbal gain Gain q21.31-qter; MYCN Non-amplified; ALK F1174L; TP53 WT	NBL, MYCN non-amplified
NA	MARIS_JE9T5LOF	Maris_P0002	873	NA	NA	SK-N-BE2	Maris	Maris_P0002_SK-N-BE2_Derived Cell Line_Progressive_NA_NA	1p36 del cnLOH p21.3-pter; 3p26 del Loss p14.2-pter; 11q23 del Gain/AI q13.1-qter; 17q21-qter unbal gain Gain q12-qter; MYCN Amplified; ALK WT; TP53 C135F	NBL, MYCN amplified
NA	MARIS_WQRZBZ4G	Maris_P0002	544.81	NA	NA	SK-N-BE2-C	Maris	Maris_P0002_SK-N-BE2-C_Derived Cell Line_Progressive_NA_NA	1p36 del cnLOH p21.3-pter; 3p26 del Loss p14.2-pter; 11q23 del LOH q11-qter, Gain q13.4-qter; 17q21-qter unbal gain Gain q12-qter; MYCN Amplified; ALK WT; TP53 C135F	NBL, MYCN amplified
NA	MARIS_7NZCWMJE	Maris_P0003	674.77	NA	NA	CHP-134	Maris	Maris_P0003_CHP-134_Derived Cell Line_Progressive_NA_NA	1p36 del LOH p32.3-pter, Gain p34.3-p36.22, Loss p36.22-pter; 3p26 del Gain/AI p26.3; 11q23 del None; 17q21-qter unbal gain Gain q12-qter; MYCN Amplified; ALK WT; TP53 WT	NBL, MYCN amplified
NA	MARIS_SXL48UGF	Maris_P0004	512.12	NA	NA	CHP-212	Maris	Maris_P0004_CHP-212_Derived Cell Line_Unknown_NA_NA	1p36 del Loss p13.2-pter; 3p26 del Gain/AI p26.3; 11q23 del cnLOH 23.3; 17q21-qter unbal gain Gain q12-qter; MYCN Amplified; ALK WT; TP53 WT	NBL, MYCN amplified
NA	MARIS_NMSC6BVZ	Maris_P0005	465.46	NA	NA	IMR-32	Maris	Maris_P0005_IMR-32_Derived Cell Line_Progressive_NA_NA	1p36 del Loss p32.3-pter; 3p26 del Loss p12.3; 11q23 del cnLOH q23.1; 17q21-qter unbal gain Gain q21.2-qter; MYCN Amplified; ALK WT; TP53 WT	NBL, MYCN amplified
NA	MARIS_VX4JCU78	Maris_P0005	369.16	NA	NA	IMR-05	Maris	Maris_P0005_IMR-05_Derived Cell Line_Progressive_NA_NA	1p36 del Gain+LOH p32.3-pter; 3p26 del Gain/AI p24.3-26.3; 11q23 del Loss q22.1-qter; 17q21-qter unbal gain Gain q21.2-qter; MYCN Amplified; ALK WT; TP53 WT	NBL, MYCN amplified
NA	MARIS_X2ET87GI	Maris_P0006	742.24	NA	NA	KELLY	Maris	Maris_P0006_KELLY_Derived Cell Line_Unknown_NA_NA	1p36 del LOH p21.3-pter, Loss p36.32, Gain p36.33; 3p26 del Loss p26.2; 11q23 del Loss q23.3-qter; 17q21-qter unbal gain Gain q21.2-qter; MYCN Amplified; ALK F1174L; TP53 P177T	NBL, MYCN amplified
NA	MARIS_54FAKEIN	Maris_P0007	13.16	NA	NA	COG-N-534	Maris	Maris_P0007_COG-N-534_Derived Cell Line_Unknown_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Non-amplified; ALK Unknown; TP53 Unknown	NBL, MYCN non-amplified
NA	MARIS_6UV3BJAL	Maris_P0008	1134.68	NA	NA	COG-N-573	Maris	Maris_P0008_COG-N-573_Derived Cell Line_Unknown_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Amplified; ALK Unknown; TP53 Unknown	NBL, MYCN amplified
NA	MARIS_HK31CBVO	Maris_P0009	1399.29	NA	NA	LA-N-5	Maris	Maris_P0009_LA-N-5_Derived Cell Line_Progressive_NA_NA	1p36 del Loss p33-pter; 3p26 del None; 11q23 del None; 17q21-qter unbal gain Gain q21.2-qter; MYCN Amplified; ALK R1275Q; TP53 WT	NBL, MYCN amplified
NA	MARIS_LJRX2KUQ	Maris_P0010	3.95	NA	NA	LA-N-6	Maris	Maris_P0010_LA-N-6_Derived Cell Line_Progressive_NA_NA	1p36 del p36.12-pter, cnLOH p35.3-p36.11; 3p26 del Loss p14.3-pter; 11q23 del Loss q13.4-qter; 17q21-qter unbal gain Gain q12-qter; MYCN Non-amplified; ALK WT; TP53 WT	NBL, MYCN non-amplified
NA	MARIS_6ZJTUIGZ	Maris_P0011	328.66	NA	NA	NB-1	Maris	Maris_P0011_NB-1_Derived Cell Line_Progressive_NA_NA	1p36 del Loss p32.2-pter; 3p26 del Gain p24.1-pter; 11q23 del cnLOH q23.1; 17q21-qter unbal gain Gain q22-qter; MYCN Amplified; ALK WT; amplified; TP53 WT	NBL, MYCN amplified
NA	MARIS_5YY8GILQ	Maris_P0012	0.81	NA	NA	NB-69	Maris	Maris_P0012_NB-69_Derived Cell Line_Unknown_NA_NA	1p36 del Loss p13.3-pter; 3p26 del None; 11q23 del cnLOH q23.1, q23.3; 17q21-qter unbal gain Gain q12-qter; MYCN Non-amplified; ALK WT; TP53 WT	NBL, MYCN non-amplified
NA	MARIS_MWYH16EQ	Maris_P0013	44.34	NA	NA	NBL-S	Maris	Maris_P0013_NBL-S_Derived Cell Line_Unknown_NA_NA	1p36 del None; 3p26 del None; 11q23 del Loss q14.1-qter; 17q21-qter unbal gain None; MYCN Non-amplified; ALK WT; TP53 WT	NBL, MYCN non-amplified
NA	MARIS_TDY23ZA5	Maris_P0014	823.02	NA	NA	NGP	Maris	Maris_P0014_NGP_Derived Cell Line_Progressive_NA_NA	1p36 del cnLOH p32.3-pter; 3p26 del Gain p25.3-pter; 11q23 del Loss q22.1-qter; 17q21-qter unbal gain Gain q21.1-qter; MYCN Amplified; ALK WT; TP53 A159D, C141W	NBL, MYCN amplified
NA	MARIS_IICVUNN8	Maris_P0015	74.04	NA	NA	NLF	Maris	Maris_P0015_NLF_Derived Cell Line_Unknown_NA_NA	1p36 del Loss p32.2-pter; 3p26 del Loss/AI p26.1, AI p26.2, Gain 26.3; 11q23 del Loss/AI q23.3-qter; 17q21-qter unbal gain Gain q21.2-qter; MYCN Amplified; ALK WT; TP53 V203M	NBL, MYCN non-amplified
NA	MARIS_IJBHSKKC	Maris_P0016	534.85	NA	NA	NMB	Maris	Maris_P0016_NMB_Derived Cell Line_Unknown_NA_NA	1p36 del cnLOH p34.2-pter; 3p26 del None; 11q23 del Loss q21-qter; 17q21-qter unbal gain LOH/Gain q11.2-qter; MYCN Amplified; ALK WT; TP53 G245S	NBL, MYCN amplified
NA	MARIS_RMULBCDT	Maris_P0017	0.08	NA	NA	SK-N-AS	Maris	Maris_P0017_SK-N-AS_Derived Cell Line_Progressive_NA_NA	1p36 del Loss p36.22-36.32; 3p26 del Loss p14.2-pter; 11q23 del q13.4-qter; 17q21-qter unbal gain Gain q21.31-qter; MYCN Non-amplified; ALK WT; TP53 H168R	NBL, MYCN non-amplified
NA	MARIS_ICP9L0D7	Maris_P0018	359.6	NA	NA	SK-N-DZ	Maris	Maris_P0018_SK-N-DZ_Derived Cell Line_Progressive_NA_NA	1p36 del None; 3p26 del Gain/AI p26.1-pter; 11q23 del Loss q21-qter; 17q21-qter unbal gain Gain q21.2-qter; MYCN Amplified; ALK WT; TP53 R110L	NBL, MYCN amplified
NA	MARIS_H8FYX6YM	Maris_P0019	28.28	NA	NA	SK-N-FI	Maris	Maris_P0019_SK-N-FI_Derived Cell Line_Progressive_NA_NA	1p36 del None; 3p26 del None; 11q23 del None; 17q21-qter unbal gain Gain q21.31-qter; MYCN Non-amplified; ALK WT; TP53 M246R	NBL, MYCN non-amplified
NA	MARIS_GKS38MPB	Maris_P0020	553.22	NA	NA	SMS-KAN	Maris	Maris_P0020_SMS-KAN_Derived Cell Line_Unknown_NA_NA	1p36 del Loss p13.3-pter; 3p26 del None; 11q23 del Loss q14.2-q23.3; 17q21-qter unbal gain Gain q11.1-qter; MYCN Amplified; ALK WT; TP53 WT	NBL, MYCN amplified
NA	MARIS_XVVK4ZCI	Maris_P0021	1116.65	NA	NA	SMS-SAN	Maris	Maris_P0021_SMS-SAN_Derived Cell Line_Progressive_NA_NA	1p36 del Loss p32.3-pter; 3p26 del None; 11q23 del Loss q25; 17q21-qter unbal gain Gain q21.2-qter; MYCN Amplified; ALK F1174L; TP53 WT	NBL, MYCN amplified
TARGET-30-PAHYWC-01A-01W	NA	PAHYWC	NA	35	amplification	01	TARGET	PAHYWC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAICGF-01A-01W	NA	PAICGF	NA	2	neutral	01	TARGET	PAICGF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAIFCS-01A-01W	NA	PAIFCS	NA	2	loss	01	TARGET	PAIFCS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAIFXV-01A-01D	TARGET-30-PAIFXV-01A-01R	PAIFXV	3.17	3	gain	01	TARGET	PAIFXV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAILNU-01A-01W	NA	PAILNU	NA	3	gain	01	TARGET	PAILNU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAIMDT-01A-01W	NA	PAIMDT	NA	2	neutral	01	TARGET	PAIMDT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAINLN-01A-01W	NA	PAINLN	NA	3	gain	01	TARGET	PAINLN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAIPGU-01A-01W	TARGET-30-PAIPGU-01A-01R	PAIPGU	17.57	3	gain	01	TARGET	PAIPGU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PAISNS-01A-01R	PAISNS	35.59	NA	NA	01	TARGET	PAISNS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAISSH-01A-01W	NA	PAISSH	NA	30	amplification	01	TARGET	PAISSH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAITCI-01A-01W	TARGET-30-PAITCI-01A-01R	PAITCI	17.43	2	loss	01	TARGET	PAITCI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAITEG-01A-01W	TARGET-30-PAITEG-01A-01R	PAITEG	1.24	2	neutral	01	TARGET	PAITEG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAIVHE-01A-01W	TARGET-30-PAIVHE-01A-01R	PAIVHE	39.72	2	loss	01	TARGET	PAIVHE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAIWRB-01A-01D	NA	PAIWRB	NA	225	amplification	01	TARGET	PAIWRB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAIXIF-01A-01W	NA	PAIXIF	NA	3	gain	01	TARGET	PAIXIF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAIXNC-01A-01W	NA	PAIXNC	NA	3	gain	01	TARGET	PAIXNC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAIXNV-01A-01W	NA	PAIXNV	NA	2	neutral	01	TARGET	PAIXNV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAIXRK-01A-01W	NA	PAIXRK	NA	66	amplification	01	TARGET	PAIXRK_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAKFUY-01A-01W	NA	PAKFUY	NA	3	gain	01	TARGET	PAKFUY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAKGKH-01A-01W	NA	PAKGKH	NA	3	neutral	01	TARGET	PAKGKH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAKHCF-01A-01W	NA	PAKHCF	NA	3	gain	01	TARGET	PAKHCF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAKHHB-01A-01W	NA	PAKHHB	NA	84	amplification	01	TARGET	PAKHHB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAKIPY-01A-01W	NA	PAKIPY	NA	2	neutral	01	TARGET	PAKIPY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAKJRE-01A-01W	NA	PAKJRE	NA	2	neutral	01	TARGET	PAKJRE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAKVUY-01A-01D	NA	PAKVUY	NA	2	neutral	01	TARGET	PAKVUY_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
TARGET-30-PAKXDZ-01A-01W	NA	PAKXDZ	NA	37	amplification	01	TARGET	PAKXDZ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAKYZS-01A-01W	TARGET-30-PAKYZS-01A-01R	PAKYZS	9.23	2	neutral	01	TARGET	PAKYZS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAKZRE-01A-01W	NA	PAKZRE	NA	43	amplification	01	TARGET	PAKZRE_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAKZRF-01A-01W	NA	PAKZRF	NA	3	loss	01	TARGET	PAKZRF_01_Solid Tissue_Primary Tumor	NA	NBL, To be classified
NA	TARGET-30-PAKZRH-01A-01R	PAKZRH	19.5	NA	NA	01	TARGET	PAKZRH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALAKE-01A-01W	NA	PALAKE	NA	115	amplification	01	TARGET	PALAKE_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PALAKM-01A-01W	NA	PALAKM	NA	2	loss	01	TARGET	PALAKM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALBFW-01A-01W	TARGET-30-PALBFW-01A-01R	PALBFW	22.9	2	neutral	01	TARGET	PALBFW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALCBW-01A-01W	TARGET-30-PALCBW-01A-01R	PALCBW	3.51	2	loss	01	TARGET	PALCBW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALETP-01A-01W	TARGET-30-PALETP-01A-01R	PALETP	35.31	2	neutral	01	TARGET	PALETP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALEVG-01A-01W	TARGET-30-PALEVG-01A-01R	PALEVG	732.82	44	amplification	01	TARGET	PALEVG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PALFPI-01A-01W	NA	PALFPI	NA	3	neutral	01	TARGET	PALFPI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALHVD-01A-01W	NA	PALHVD	NA	4	gain	01	TARGET	PALHVD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALIIN-01A-01W	TARGET-30-PALIIN-01A-01R	PALIIN	55.37	2	loss	01	TARGET	PALIIN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALJPX-01A-01W	NA	PALJPX	NA	27	amplification	01	TARGET	PALJPX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PALJUV-01A-01W	NA	PALJUV	NA	2	loss	01	TARGET	PALJUV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PALKUC-01A-01R	PALKUC	147.41	NA	NA	01	TARGET	PALKUC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PALNLU-01A-01W	NA	PALNLU	NA	3	loss	01	TARGET	PALNLU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PALNVP-01A-01R	PALNVP	22.36	NA	NA	01	TARGET	PALNVP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALPGG-01A-01W	NA	PALPGG	NA	171	amplification	01	TARGET	PALPGG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PALRSD-01A-01D	NA	PALRSD	NA	2	neutral	01	TARGET	PALRSD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALSAE-01A-01W	NA	PALSAE	NA	3	neutral	01	TARGET	PALSAE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALTEG-01A-01W	TARGET-30-PALTEG-01A-01R	PALTEG	17.22	2	neutral	01	TARGET	PALTEG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALTYB-01A-01W	NA	PALTYB	NA	2	neutral	01	TARGET	PALTYB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALUDH-01A-01W	NA	PALUDH	NA	2	loss	01	TARGET	PALUDH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PALUYS-01A-01R	PALUYS	64.75	NA	NA	01	TARGET	PALUYS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PALVKK-01A-01R	PALVKK	11.63	NA	NA	01	TARGET	PALVKK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALWIP-01A-01W	NA	PALWIP	NA	2	loss	01	TARGET	PALWIP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALWVJ-01A-01W	TARGET-30-PALWVJ-01A-01R	PALWVJ	8.86	2	neutral	01	TARGET	PALWVJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALXHW-01A-01W	NA	PALXHW	NA	3	neutral	01	TARGET	PALXHW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALXMM-01A-01W	NA	PALXMM	NA	1	loss	01	TARGET	PALXMM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PALXTB-01A-01R	PALXTB	35.21	NA	NA	01	TARGET	PALXTB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PALZRG-01A-01W	NA	PALZRG	NA	57	amplification	01	TARGET	PALZRG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PALZSL-01A-01W	NA	PALZSL	NA	69	amplification	01	TARGET	PALZSL_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PALZZV-01A-01W	TARGET-30-PALZZV-01A-01R	PALZZV	818.77	86	amplification	01	TARGET	PALZZV_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAMBAC-01A-01W	NA	PAMBAC	NA	101	amplification	01	TARGET	PAMBAC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
NA	TARGET-30-PAMBMJ-01A-01R	PAMBMJ	71.2	NA	NA	01	TARGET	PAMBMJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN non-amplified
TARGET-30-PAMCXF-01A-01W	NA	PAMCXF	NA	2	loss	01	TARGET	PAMCXF_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
TARGET-30-PAMDAL-01A-01W	NA	PAMDAL	NA	50	amplification	01	TARGET	PAMDAL_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
NA	TARGET-30-PAMEZH-01A-01R	PAMEZH	121.89	NA	NA	01	TARGET	PAMEZH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN non-amplified
TARGET-30-PAMMWD-01A-01W	NA	PAMMWD	NA	260	amplification	01	TARGET	PAMMWD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAMMXF-01A-01W	TARGET-30-PAMMXF-01A-01R	PAMMXF	482.57	2	neutral	01	TARGET	PAMMXF_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
NA	TARGET-30-PAMNLH-01A-01R	PAMNLH	29.77	NA	NA	01	TARGET	PAMNLH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAMNYX-01A-01D	NA	PAMNYX	NA	2	loss	01	TARGET	PAMNYX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAMUTD-01A-01W	NA	PAMUTD	NA	55	amplification	01	TARGET	PAMUTD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAMVLG-01A-01D	NA	PAMVLG	NA	3	neutral	01	TARGET	PAMVLG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAMVRA-01A-01W	TARGET-30-PAMVRA-01A-01R	PAMVRA	57.44	2	loss	01	TARGET	PAMVRA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAMYCE-01A-01W	TARGET-30-PAMYCE-01A-01R	PAMYCE	24.37	2	loss	01	TARGET	PAMYCE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAMZGT-01A-01W	TARGET-30-PAMZGT-01A-01R	PAMZGT	214.79	23	amplification	01	TARGET	PAMZGT_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAMZMG-01A-01W	TARGET-30-PAMZMG-01A-01R	PAMZMG	594.01	44	amplification	01	TARGET	PAMZMG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PANBCI-01A-01W	NA	PANBCI	NA	28	amplification	01	TARGET	PANBCI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
NA	TARGET-30-PANBJH-01A-01R	PANBJH	81.56	NA	NA	01	TARGET	PANBJH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANBMJ-01A-01W	TARGET-30-PANBMJ-01A-01R	PANBMJ	3.53	2	neutral	01	TARGET	PANBMJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANBSP-01A-01W	TARGET-30-PANBSP-01A-01R	PANBSP	45.6	3	neutral	01	TARGET	PANBSP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PANGXK-01A-01R	PANGXK	3.28	NA	NA	01	TARGET	PANGXK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANIPC-06A-01W	NA	PANIPC	NA	35	amplification	06	TARGET	PANIPC_06_Solid Tissue_Metastatic	MYCN amp	NBL, MYCN amplified
NA	TARGET-30-PANJLH-01A-01R	PANJLH	403.51	NA	NA	01	TARGET	PANJLH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PANKFE-01A-01W	TARGET-30-PANKFE-01A-01R	PANKFE	4.39	2	neutral	01	TARGET	PANKFE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANLET-01A-01D	TARGET-30-PANLET-01A-01R	PANLET	31.45	2	loss	01	TARGET	PANLET_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PANNMS-01A-01R	PANNMS	73.96	NA	NA	01	TARGET	PANNMS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANPVI-01A-01W	NA	PANPVI	NA	2	loss	01	TARGET	PANPVI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANRHJ-01A-01W	TARGET-30-PANRHJ-01A-01R	PANRHJ	22.58	2	neutral	01	TARGET	PANRHJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PANRRW-01A-01R	PANRRW	42.67	NA	NA	01	TARGET	PANRRW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANRVJ-01A-01D	TARGET-30-PANRVJ-01A-01R	PANRVJ	26.77	2	loss	01	TARGET	PANRVJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANSBN-01A-01D	TARGET-30-PANSBN-01A-01R	PANSBN	0.64	2	neutral	01	TARGET	PANSBN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANUIF-01A-01D	TARGET-30-PANUIF-01A-01R	PANUIF	11.99	3	gain	01	TARGET	PANUIF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANUKV-01A-01W	NA	PANUKV	NA	2	neutral	01	TARGET	PANUKV_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
TARGET-30-PANWRR-01A-01D	TARGET-30-PANWRR-01A-01R	PANWRR	40.86	2	neutral	01	TARGET	PANWRR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANXJL-01A-01D	TARGET-30-PANXJL-01A-01R	PANXJL	1.55	2	loss	01	TARGET	PANXJL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANYBL-01A-01W	NA	PANYBL	NA	2	neutral	01	TARGET	PANYBL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANYGR-01A-01W	TARGET-30-PANYGR-01A-01R	PANYGR	30.92	2	loss	01	TARGET	PANYGR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANZPV-01A-01W	TARGET-30-PANZPV-01A-01R	PANZPV	12.01	2	loss	01	TARGET	PANZPV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PANZRV-01A-01R	PANZRV	73.06	NA	NA	01	TARGET	PANZRV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PANZVU-01A-01W	TARGET-30-PANZVU-01A-01R	PANZVU	37.11	2	loss	01	TARGET	PANZVU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPBGH-01A-01W	TARGET-30-PAPBGH-01A-01R	PAPBGH	0.47	2	loss	01	TARGET	PAPBGH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPBJE-01A-01D	TARGET-30-PAPBJE-01A-01R	PAPBJE	703.67	216	amplification	01	TARGET	PAPBJE_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPBJT-01A-01W	NA	PAPBJT	NA	2	loss	01	TARGET	PAPBJT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPBZI-01A-01W	TARGET-30-PAPBZI-01A-01R	PAPBZI	22.34	4	gain	01	TARGET	PAPBZI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPCTS-01A-01D	TARGET-30-PAPCTS-01A-01R	PAPCTS	1530.68	129	amplification	01	TARGET	PAPCTS_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPEFE-01A-01W	TARGET-30-PAPEFE-01A-01R	PAPEFE	235.04	7	amplification	01	TARGET	PAPEFE_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPHPE-01A-01W	TARGET-30-PAPHPE-01A-01R	PAPHPE	6.12	3	neutral	01	TARGET	PAPHPE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PAPICY-01A-01R	PAPICY	52.53	NA	NA	01	TARGET	PAPICY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPKWN-01A-01W	TARGET-30-PAPKWN-01A-01R	PAPKWN	51.31	13	amplification	01	TARGET	PAPKWN_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPKXS-01A-01D	TARGET-30-PAPKXS-01A-01R	PAPKXS	138.23	3	gain	01	TARGET	PAPKXS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPLSD-01A-01D	TARGET-30-PAPLSD-01A-01R	PAPLSD	22.99	3	gain	01	TARGET	PAPLSD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPNEP-01A-01W	NA	PAPNEP	NA	42	amplification	01	TARGET	PAPNEP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPPKJ-01A-01W	NA	PAPPKJ	NA	4	gain	01	TARGET	PAPPKJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPREJ-01A-01D	NA	PAPREJ	NA	181	amplification	01	TARGET	PAPREJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPRMJ-01A-01D	NA	PAPRMJ	NA	2	neutral	01	TARGET	PAPRMJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPRPR-01A-01D	NA	PAPRPR	NA	69	amplification	01	TARGET	PAPRPR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPRXW-01A-01D	NA	PAPRXW	NA	29	amplification	01	TARGET	PAPRXW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPSMC-01A-01W	NA	PAPSMC	NA	34	amplification	01	TARGET	PAPSMC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPTAN-01A-01D	TARGET-30-PAPTAN-01A-01R	PAPTAN	16.17	2	neutral	01	TARGET	PAPTAN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPTCR-01A-01D	TARGET-30-PAPTCR-01A-01R	PAPTCR	5.71	2	neutral	01	TARGET	PAPTCR_01_Solid Tissue_Primary Tumor	NA	NBL, MYCN non-amplified
NA	TARGET-30-PAPTDH-01A-01R	PAPTDH	38.65	NA	NA	01	TARGET	PAPTDH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPTFZ-01A-01D	TARGET-30-PAPTFZ-01A-01R	PAPTFZ	841.05	125	amplification	01	TARGET	PAPTFZ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPTJB-01A-01D	NA	PAPTJB	NA	4	gain	01	TARGET	PAPTJB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPTLA-01A-01D	NA	PAPTLA	NA	3	gain	01	TARGET	PAPTLA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPTLV-01A-01D	TARGET-30-PAPTLV-01A-01R	PAPTLV	255.44	24	amplification	01	TARGET	PAPTLV_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
NA	TARGET-30-PAPUEB-01A-01R	PAPUEB	20.09	NA	NA	01	TARGET	PAPUEB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPUJU-01A-01D	NA	PAPUJU	NA	2	loss	01	TARGET	PAPUJU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PAPUNH-01A-01R	PAPUNH	2481.33	NA	NA	01	TARGET	PAPUNH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPUWY-01A-01D	TARGET-30-PAPUWY-01A-01R	PAPUWY	48.51	2	loss	01	TARGET	PAPUWY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PAPVEB-04A-01R	PAPVEB	11.44	NA	NA	04	TARGET	PAPVEB_04_Bone Marrow_Recurrence	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPVFD-01A-01D	TARGET-30-PAPVFD-01A-01R	PAPVFD	76.15	2	loss	01	TARGET	PAPVFD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPVRN-01A-01D	TARGET-30-PAPVRN-01A-01R	PAPVRN	6.59	2	loss	01	TARGET	PAPVRN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPVXS-01A-01D	TARGET-30-PAPVXS-01A-01R	PAPVXS	36.95	3	neutral	01	TARGET	PAPVXS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAPWFY-01A-01D	NA	PAPWFY	NA	34	amplification	01	TARGET	PAPWFY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPYNZ-01A-01D	NA	PAPYNZ	NA	69	amplification	01	TARGET	PAPYNZ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPZFW-01A-01D	NA	PAPZFW	NA	2	loss	01	TARGET	PAPZFW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PAPZYP-01A-01R	PAPZYP	404.52	NA	NA	01	TARGET	PAPZYP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAPZYZ-01A-01D	TARGET-30-PAPZYZ-01A-01R	PAPZYZ	273.22	131	amplification	01	TARGET	PAPZYZ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PARABJ-01A-01D	NA	PARABJ	NA	2	loss	01	TARGET	PARABJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PARACM-01A-01R	PARACM	35.88	NA	NA	01	TARGET	PARACM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARACR-01A-01D	NA	PARACR	NA	3	gain	01	TARGET	PARACR_01_Solid Tissue_Primary Tumor	NA	NBL, To be classified
TARGET-30-PARACS-01A-01D	TARGET-30-PARACS-01A-01R	PARACS	36.69	3	neutral	01	TARGET	PARACS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARAMT-01A-01D	TARGET-30-PARAMT-01A-01R	PARAMT	73.4	3	neutral	01	TARGET	PARAMT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARASL-01A-01D	NA	PARASL	NA	3	gain	01	TARGET	PARASL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PARBAJ-01A-01R	PARBAJ	20.35	NA	NA	01	TARGET	PARBAJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PARBAJ-02A-01R	PARBAJ	11.17	NA	NA	02	TARGET	PARBAJ_02_Solid Tissue_Recurrence	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARBGP-01A-01D	TARGET-30-PARBGP-01A-01R	PARBGP	59.05	2	loss	01	TARGET	PARBGP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARBLH-01A-01D	NA	PARBLH	NA	2	loss	01	TARGET	PARBLH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARCRR-01A-01D	NA	PARCRR	NA	3	gain	01	TARGET	PARCRR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARDCK-01A-01D	TARGET-30-PARDCK-01A-01R	PARDCK	8.07	2	loss	01	TARGET	PARDCK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARDIW-01A-01D	TARGET-30-PARDIW-01A-01R	PARDIW	22.26	2	loss	01	TARGET	PARDIW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARDVT-01A-01D	NA	PARDVT	NA	3	neutral	01	TARGET	PARDVT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARDYU-01A-01D	NA	PARDYU	NA	213	amplification	01	TARGET	PARDYU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAREAG-01A-01D	NA	PAREAG	NA	2	neutral	01	TARGET	PAREAG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARETE-01A-01D	NA	PARETE	NA	2	loss	01	TARGET	PARETE_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
NA	TARGET-30-PARFRE-01A-01R	PARFRE	37.8	NA	NA	01	TARGET	PARFRE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARFWB-01A-01D	TARGET-30-PARFWB-01A-01R	PARFWB	34.21	2	neutral	01	TARGET	PARFWB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARGHY-01A-01D	NA	PARGHY	NA	2	neutral	01	TARGET	PARGHY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARGKK-01A-01D	TARGET-30-PARGKK-01A-01R	PARGKK	32.9	2	neutral	01	TARGET	PARGKK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARGZK-01A-01D	NA	PARGZK	NA	2	neutral	01	TARGET	PARGZK_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
NA	TARGET-30-PARHAM-01A-01R	PARHAM	29.37	NA	NA	01	TARGET	PARHAM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PARHAM-02A-01R	PARHAM	11.26	NA	NA	02	TARGET	PARHAM_02_Solid Tissue_Recurrence	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARHDE-01A-01D	NA	PARHDE	NA	2	neutral	01	TARGET	PARHDE_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
TARGET-30-PARHUX-01A-01D	NA	PARHUX	NA	3	gain	01	TARGET	PARHUX_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
TARGET-30-PARJEN-01A-01D	NA	PARJEN	NA	35	amplification	01	TARGET	PARJEN_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PARJMX-01A-01D	NA	PARJMX	NA	2	neutral	01	TARGET	PARJMX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PARJVP-01A-01R	PARJVP	70.22	NA	NA	01	TARGET	PARJVP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARKAG-01A-01D	NA	PARKAG	NA	99	amplification	01	TARGET	PARKAG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PARKGJ-01A-01D	TARGET-30-PARKGJ-01A-01R	PARKGJ	10.02	3	gain	01	TARGET	PARKGJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARKNP-01A-01D	NA	PARKNP	NA	2	loss	01	TARGET	PARKNP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARKZF-01A-01D	NA	PARKZF	NA	103	amplification	01	TARGET	PARKZF_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PARLMK-01A-01D	NA	PARLMK	NA	2	loss	01	TARGET	PARLMK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARLTG-01A-01D	NA	PARLTG	NA	3	neutral	01	TARGET	PARLTG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARMDD-01A-01D	NA	PARMDD	NA	2	loss	01	TARGET	PARMDD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARMLF-01A-01D	NA	PARMLF	NA	3	neutral	01	TARGET	PARMLF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARMPP-01A-01D	NA	PARMPP	NA	2	neutral	01	TARGET	PARMPP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARNLJ-01A-01D	NA	PARNLJ	NA	101	amplification	01	TARGET	PARNLJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
NA	TARGET-30-PARNNC-01A-01R	PARNNC	42.52	NA	NA	01	TARGET	PARNNC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARNNG-01A-01D	NA	PARNNG	NA	2	loss	01	TARGET	PARNNG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARNTS-01A-01D	NA	PARNTS	NA	32	amplification	01	TARGET	PARNTS_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PARPGU-01A-01D	NA	PARPGU	NA	2	neutral	01	TARGET	PARPGU_01_Solid Tissue_Primary Tumor	NA	NBL, To be classified
TARGET-30-PARPUF-01A-01D	NA	PARPUF	NA	NA	NA	01	TARGET	PARPUF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARRLH-01A-01D	NA	PARRLH	NA	3	gain	01	TARGET	PARRLH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARSBI-01A-01D	TARGET-30-PARSBI-01A-01R	PARSBI	13.29	2	loss	01	TARGET	PARSBI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARSRJ-01A-01D	NA	PARSRJ	NA	26	amplification	01	TARGET	PARSRJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PARSVF-01A-01D	NA	PARSVF	NA	NA	NA	01	TARGET	PARSVF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARSXI-01A-01D	NA	PARSXI	NA	NA	NA	01	TARGET	PARSXI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARSZV-01A-01D	NA	PARSZV	NA	NA	NA	01	TARGET	PARSZV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARTCE-01A-01D	NA	PARTCE	NA	NA	NA	01	TARGET	PARTCE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARTPF-01A-01D	NA	PARTPF	NA	NA	NA	01	TARGET	PARTPF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_4RX1AAVV	BS_S0B4WASX	PARTRP	16.43	NA	NA	01	GMKF	PARTRP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARTRP-01A-01D	BS_S0B4WASX	PARTRP	16.43	NA	NA	01	TARGET	PARTRP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARTYI-01A-01D	NA	PARTYI	NA	NA	NA	01	TARGET	PARTYI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARTZW-01A-01D	NA	PARTZW	NA	NA	NA	01	TARGET	PARTZW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARUCL-01A-01D	NA	PARUCL	NA	NA	NA	01	TARGET	PARUCL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARUCM-01A-01D	NA	PARUCM	NA	NA	NA	01	TARGET	PARUCM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_J2DA5W77	NA	PARUFS	NA	3	gain	01	GMKF	PARUFS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARUGX-01A-01D	NA	PARUGX	NA	NA	NA	01	TARGET	PARUGX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARUPN-01A-01D	NA	PARUPN	NA	2	neutral	01	TARGET	PARUPN_01_Solid Tissue_Primary Tumor	NA	NBL, To be classified
TARGET-30-PARUPT-01A-01D	NA	PARUPT	NA	NA	NA	01	TARGET	PARUPT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARURB-01A-01D	NA	PARURB	NA	3	gain	01	TARGET	PARURB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_K2K5YSDS	BS_S5KDWVEA	PARUTJ	0.41	NA	NA	01	GMKF	PARUTJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARUTJ-01A-01D	BS_S5KDWVEA	PARUTJ	0.41	NA	NA	01	TARGET	PARUTJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARUTX-01A-01D	NA	PARUTX	NA	NA	NA	01	TARGET	PARUTX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_808H2FQN	BS_ERHKS2Y7	PARUZA	0.49	NA	NA	01	GMKF	PARUZA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARVFJ-01A-01D	NA	PARVFJ	NA	2	loss	01	TARGET	PARVFJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARVHG-01A-01D	NA	PARVHG	NA	NA	NA	01	TARGET	PARVHG_01_Solid Tissue_Primary Tumor	NA	NBL, To be classified
TARGET-30-PARVIH-01A-01D	NA	PARVIH	NA	NA	NA	01	TARGET	PARVIH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARVLK-01A-01D	TARGET-30-PARVLK-01A-01R	PARVLK	11.15	2	loss	01	TARGET	PARVLK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARVMU-01A-01D	NA	PARVMU	NA	NA	NA	01	TARGET	PARVMU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARVNT-01A-01D	NA	PARVNT	NA	6	amplification	01	TARGET	PARVNT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN amplified
BS_Z862V8M7	BS_NPVE58AT	PARVPD	12.89	3	gain	01	GMKF	PARVPD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARVVM-09A-01D	NA	PARVVM	NA	NA	NA	09	TARGET	PARVVM_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PARVWL-01A-01D	NA	PARVWL	NA	NA	NA	01	TARGET	PARVWL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_8FYZMP93	NA	PARVZT	NA	NA	NA	01	GMKF	PARVZT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARVZT-01A-01D	NA	PARVZT	NA	NA	NA	01	TARGET	PARVZT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARWAM-01A-01D	NA	PARWAM	NA	NA	NA	01	TARGET	PARWAM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARWBC-01A-01D	NA	PARWBC	NA	NA	NA	01	TARGET	PARWBC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARWEH-01A-01D	NA	PARWEH	NA	NA	NA	01	TARGET	PARWEH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_C8T56CWR	BS_DBXCETW2	PARWEV	33.86	NA	NA	01	GMKF	PARWEV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARWEV-01A-01D	BS_DBXCETW2	PARWEV	33.86	NA	NA	01	TARGET	PARWEV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARWTY-01A-01D	NA	PARWTY	NA	NA	NA	01	TARGET	PARWTY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARXAX-01A-01D	NA	PARXAX	NA	NA	NA	01	TARGET	PARXAX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_75HW641M	NA	PARXDW	NA	3	gain	01	GMKF	PARXDW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARXLL-01A-01D	NA	PARXLL	NA	NA	NA	01	TARGET	PARXLL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARXLN-01A-01D	NA	PARXLN	NA	NA	NA	01	TARGET	PARXLN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARXMH-01A-01D	NA	PARXMH	NA	NA	NA	01	TARGET	PARXMH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARXMM-01A-01D	NA	PARXMM	NA	NA	NA	01	TARGET	PARXMM_01_Solid Tissue_Primary Tumor	NA	NBL, To be classified
BS_29DZNQYC	BS_3N0ZS3G3	PARXPD	24.86	3	loss	01	GMKF	PARXPD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARXPD-01A-01D	BS_3N0ZS3G3	PARXPD	24.86	NA	NA	01	TARGET	PARXPD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARXVA-01A-01D	NA	PARXVA	NA	NA	NA	01	TARGET	PARXVA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARXXC-01A-01D	NA	PARXXC	NA	NA	NA	01	TARGET	PARXXC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARXZA-01A-01D	NA	PARXZA	NA	NA	NA	01	TARGET	PARXZA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_29MQMSCM	BS_YZJ5YQ12	PARYAG	1.84	NA	NA	01	GMKF	PARYAG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_1G5N5R8S	BS_2Y28PRQC	PARYEH	22.31	3	loss	01	GMKF	PARYEH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARYEH-01A-01D	BS_2Y28PRQC	PARYEH	22.31	NA	NA	01	TARGET	PARYEH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARYNK-01A-01D	TARGET-30-PARYNK-01A-01R	PARYNK	5.63	2	neutral	01	TARGET	PARYNK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_92YFTG9R	BS_JY850J9G	PARYRJ	26.4	NA	NA	01	GMKF	PARYRJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARYRJ-01A-01D	BS_JY850J9G	PARYRJ	26.4	NA	NA	01	TARGET	PARYRJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARYSR-01A-01D	NA	PARYSR	NA	NA	NA	01	TARGET	PARYSR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PARYUK-01A-01D	NA	PARYUK	NA	NA	NA	01	TARGET	PARYUK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARYVD-01A-01D	NA	PARYVD	NA	NA	NA	01	TARGET	PARYVD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PARYWX-01A-01D	NA	PARYWX	NA	NA	NA	01	TARGET	PARYWX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARYXW-01A-01D	NA	PARYXW	NA	5	amplification	01	TARGET	PARYXW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_F6MNG2S0	BS_BG0ZDND2	PARZBH	22.7	NA	NA	01	GMKF	PARZBH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARZBH-01A-01D	BS_BG0ZDND2	PARZBH	22.7	NA	NA	01	TARGET	PARZBH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_1G3QX306	BS_FHNTKFVJ	PARZCJ	14.28	NA	NA	01	GMKF	PARZCJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_1G3QX306	TARGET-30-PARZCJ-01A-01R	PARZCJ	29.97	NA	NA	01	GMKF	PARZCJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PARZHA-01A-01R	PARZHA	68.06	NA	NA	01	TARGET	PARZHA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARZIP-01A-01D	TARGET-30-PARZIP-01A-01R	PARZIP	53.23	3	loss	01	TARGET	PARZIP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PARZKK-09A-01D	NA	PARZKK	NA	NA	NA	09	TARGET	PARZKK_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PARZMY-06A-01D	NA	PARZMY	NA	84	amplification	06	TARGET	PARZMY_06_Solid Tissue_Metastatic	MYCN amp	NBL, MYCN amplified
TARGET-30-PARZNV-01A-01D	NA	PARZNV	NA	NA	NA	01	TARGET	PARZNV_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PARZZC-01A-01D	NA	PARZZC	NA	NA	NA	01	TARGET	PARZZC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PARZZD-01A-01D	NA	PARZZD	NA	NA	NA	01	TARGET	PARZZD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASAAB-01A-01D	NA	PASAAB	NA	NA	NA	01	TARGET	PASAAB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASAAN-01A-01D	NA	PASAAN	NA	2	neutral	01	TARGET	PASAAN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_AZ6KVKC4	NA	PASAEJ	NA	NA	NA	01	GMKF	PASAEJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASAFG-01A-01D	NA	PASAFG	NA	NA	NA	01	TARGET	PASAFG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_7MXT22QP	BS_9R8GFR36	PASAGA	11.82	NA	NA	01	GMKF	PASAGA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_Z2G9EG1X	BS_AFRGW493	PASAHC	20.59	NA	NA	01	GMKF	PASAHC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASAHC-01A-01D	BS_AFRGW493	PASAHC	20.59	NA	NA	01	TARGET	PASAHC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASAJU-01A-01D	NA	PASAJU	NA	2	neutral	01	TARGET	PASAJU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASAJY-01A-01D	NA	PASAJY	NA	NA	NA	01	TARGET	PASAJY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASALE-01A-01D	NA	PASALE	NA	NA	NA	01	TARGET	PASALE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASANE-01A-01D	NA	PASANE	NA	NA	NA	01	TARGET	PASANE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASATF-01A-01D	NA	PASATF	NA	NA	NA	01	TARGET	PASATF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_J3707KE2	BS_28ZRHXX8	PASAVJ	21.16	NA	NA	01	GMKF	PASAVJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASAVJ-01A-01D	BS_28ZRHXX8	PASAVJ	21.16	NA	NA	01	TARGET	PASAVJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASAZZ-01A-01D	NA	PASAZZ	NA	NA	NA	01	TARGET	PASAZZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_JGVTE14P	BS_15ED4VDX	PASBDN	31.15	3	gain	01	GMKF	PASBDN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASBDN-01A-01D	BS_15ED4VDX	PASBDN	31.15	NA	NA	01	TARGET	PASBDN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASBGV-01A-01D	NA	PASBGV	NA	2	neutral	01	TARGET	PASBGV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_SSHQFYA8	BS_EF8F5GH8	PASBHS	23.15	3	gain	01	GMKF	PASBHS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASBJY-01A-01D	NA	PASBJY	NA	NA	NA	01	TARGET	PASBJY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASBKP-01A-01D	NA	PASBKP	NA	NA	NA	01	TARGET	PASBKP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASBMW-01A-01D	NA	PASBMW	NA	NA	NA	01	TARGET	PASBMW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_5PEA35TB	NA	PASBPN	NA	NA	NA	01	GMKF	PASBPN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASBPN-01A-01D	NA	PASBPN	NA	NA	NA	01	TARGET	PASBPN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASBYW-01A-01D	NA	PASBYW	NA	NA	NA	01	TARGET	PASBYW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASBZV-01A-01D	NA	PASBZV	NA	NA	NA	01	TARGET	PASBZV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_SYSZCYYZ	BS_97SKFHM4	PASCDX	181.39	222	amplification	01	GMKF	PASCDX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASCDX-01A-01D	BS_97SKFHM4	PASCDX	181.39	106	amplification	01	TARGET	PASCDX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASCEW-09A-01D	NA	PASCEW	NA	NA	NA	09	TARGET	PASCEW_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASCFA-01A-01D	NA	PASCFA	NA	NA	NA	01	TARGET	PASCFA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PASCFC-01A-01R	PASCFC	54.22	NA	NA	01	TARGET	PASCFC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASCFD-01A-01D	NA	PASCFD	NA	NA	NA	01	TARGET	PASCFD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_HYX0M8VM	BS_REGK1PS6	PASCGM	5.56	3	neutral	01	GMKF	PASCGM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASCIX-09A-01D	NA	PASCIX	NA	NA	NA	09	TARGET	PASCIX_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASCJJ-01A-01D	NA	PASCJJ	NA	3	neutral	01	TARGET	PASCJJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASCRK-01A-01D	NA	PASCRK	NA	NA	NA	01	TARGET	PASCRK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PASCTR-01A-01R	PASCTR	38.9	NA	NA	01	TARGET	PASCTR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_DWYR5CTE	BS_W5X4568N	PASCWD	310.39	132	amplification	01	GMKF	PASCWD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASCWD-01A-01D	BS_W5X4568N	PASCWD	310.39	NA	NA	01	TARGET	PASCWD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASCZY-01A-01D	NA	PASCZY	NA	NA	NA	01	TARGET	PASCZY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_XA3KEKC6	BS_MAJ800Q0	PASDDP	19.57	3	loss	01	GMKF	PASDDP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASDDP-01A-01D	BS_MAJ800Q0	PASDDP	19.57	NA	NA	01	TARGET	PASDDP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_H18ZNTNR	NA	PASDNT	NA	NA	NA	01	GMKF	PASDNT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_W05MC7QG	NA	PASDPN	NA	NA	NA	01	GMKF	PASDPN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASDRV-01A-01D	NA	PASDRV	NA	NA	NA	01	TARGET	PASDRV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_B6E0477K	BS_N13KZYRR	PASDYT	17.46	NA	NA	01	GMKF	PASDYT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASDYT-01A-01D	BS_N13KZYRR	PASDYT	17.46	NA	NA	01	TARGET	PASDYT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASEAR-01A-01D	NA	PASEAR	NA	NA	NA	01	TARGET	PASEAR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASEDP-01A-01D	NA	PASEDP	NA	NA	NA	01	TARGET	PASEDP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASEGA-01A-01D	TARGET-30-PASEGA-01A-01R	PASEGA	16.44	2	neutral	01	TARGET	PASEGA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASEGF-01A-01D	NA	PASEGF	NA	NA	NA	01	TARGET	PASEGF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASEJZ-01A-01D	NA	PASEJZ	NA	NA	NA	01	TARGET	PASEJZ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASESX-01A-01D	NA	PASESX	NA	NA	NA	01	TARGET	PASESX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASEVK-01A-01D	NA	PASEVK	NA	NA	NA	01	TARGET	PASEVK_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASEWX-01A-01D	NA	PASEWX	NA	NA	NA	01	TARGET	PASEWX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_X2D8S1HY	BS_8VPBB5C2	PASEWZ	36.38	3	gain	01	GMKF	PASEWZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASEWZ-01A-01D	BS_8VPBB5C2	PASEWZ	36.38	NA	NA	01	TARGET	PASEWZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASEYW-01A-01D	NA	PASEYW	NA	NA	NA	01	TARGET	PASEYW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_PQFKEKEW	BS_WR5VE59B	PASFCG	24.8	NA	NA	01	GMKF	PASFCG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASFCG-01A-01D	BS_WR5VE59B	PASFCG	24.8	NA	NA	01	TARGET	PASFCG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASFDJ-01A-01D	NA	PASFDJ	NA	NA	NA	01	TARGET	PASFDJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASFDU-01A-01D	NA	PASFDU	NA	NA	NA	01	TARGET	PASFDU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASFDV-01A-01D	NA	PASFDV	NA	NA	NA	01	TARGET	PASFDV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_KE5D12KG	BS_W3ZSVEVP	PASFEU	1.62	NA	NA	01	GMKF	PASFEU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_MCCJ3EMF	BS_Z0MTZA9K	PASFEV	32.76	3	neutral	01	GMKF	PASFEV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASFEV-01A-01D	BS_Z0MTZA9K	PASFEV	32.76	NA	NA	01	TARGET	PASFEV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASFGD-01A-01D	NA	PASFGD	NA	NA	NA	01	TARGET	PASFGD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASFGG-01A-01D	TARGET-30-PASFGG-01A-01R	PASFGG	18.94	2	neutral	01	TARGET	PASFGG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_D8H43Q28	NA	PASFHI	NA	NA	NA	01	GMKF	PASFHI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_W22EEJCZ	BS_DYHEFXJC	PASFIC	13.49	NA	NA	01	GMKF	PASFIC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_W22EEJCZ	TARGET-30-PASFIC-01A-01R	PASFIC	33.72	NA	NA	01	GMKF	PASFIC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASFKX-01A-01D	BS_6N7RPHX9	PASFKX	392.43	NA	NA	01	TARGET	PASFKX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_2X9EVKZ0	BS_6N7RPHX9	PASFKX	392.43	3	loss	01	GMKF	PASFKX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASFNF-01A-01D	NA	PASFNF	NA	NA	NA	01	TARGET	PASFNF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_MTQ7F28J	NA	PASFNY	NA	64	amplification	01	GMKF	PASFNY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASFNY-01A-01D	NA	PASFNY	NA	109	amplification	01	TARGET	PASFNY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_5BFNH9S6	BS_WHX83JW2	PASFWL	34.59	3	loss	01	GMKF	PASFWL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASFWL-01A-01D	BS_WHX83JW2	PASFWL	34.59	NA	NA	01	TARGET	PASFWL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_T9VPRPVA	BS_3KGHX57D	PASFXC	21.59	3	gain	01	GMKF	PASFXC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASFXC-01A-01D	BS_3KGHX57D	PASFXC	21.59	NA	NA	01	TARGET	PASFXC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASFXS-01A-01D	NA	PASFXS	NA	NA	NA	01	TARGET	PASFXS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASGAP-01A-01D	TARGET-30-PASGAP-01A-01R	PASGAP	5.34	2	loss	01	TARGET	PASGAP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PASGAP-02A-01R	PASGAP	10.98	NA	NA	02	TARGET	PASGAP_02_Solid Tissue_Recurrence	MYCN non-amp	NBL, MYCN non-amplified
NA	BS_43R2B7DR	PASGBE	2.34	NA	NA	01	GMKF	PASGBE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASGCD-01A-01D	NA	PASGCD	NA	NA	NA	01	TARGET	PASGCD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASGDB-01A-01D	NA	PASGDB	NA	NA	NA	01	TARGET	PASGDB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASGEE-01A-01D	NA	PASGEE	NA	NA	NA	01	TARGET	PASGEE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASGES-01A-01D	NA	PASGES	NA	NA	NA	01	TARGET	PASGES_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_QKTJ4QY9	BS_A2HY1DZA	PASGGD	13.74	NA	NA	01	GMKF	PASGGD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_P8X3GAEP	NA	PASGGI	NA	NA	NA	01	GMKF	PASGGI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASGGI-01A-01D	NA	PASGGI	NA	NA	NA	01	TARGET	PASGGI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASGHN-01A-01D	NA	PASGHN	NA	NA	NA	01	TARGET	PASGHN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASGKP-01A-01D	NA	PASGKP	NA	NA	NA	01	TARGET	PASGKP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASGNT-01A-01D	NA	PASGNT	NA	NA	NA	01	TARGET	PASGNT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_EQE447QB	NA	PASGRL	NA	3	gain	01	GMKF	PASGRL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASGUT-01A-01D	TARGET-30-PASGUT-01A-01R	PASGUT	22.29	2	loss	01	TARGET	PASGUT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_TR758MB1	NA	PASHEL	NA	53	amplification	01	GMKF	PASHEL_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
NA	TARGET-30-PASHFA-01A-01R	PASHFA	422.71	NA	NA	01	TARGET	PASHFA_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_CGGJZ5Q1	NA	PASHLP	NA	NA	NA	01	GMKF	PASHLP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_30NT6PNA	BS_6GSJCDCN	PASIIB	13.32	3	gain	01	GMKF	PASIIB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_W2BC0CVT	NA	PASIIU	NA	622	amplification	01	GMKF	PASIIU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_SY6CCX4G	BS_19PXZ71B	PASIUJ	149.73	33	amplification	01	GMKF	PASIUJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_F3ZZ4BXE	NA	PASJBY	NA	NA	NA	01	GMKF	PASJBY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_WMM0MP1J	NA	PASJRT	NA	4	gain	01	GMKF	PASJRT_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
BS_DFJYRYV1	BS_WHBM0N3Y	PASJTA	19.87	3	gain	01	GMKF	PASJTA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASJTA-01A-01D	BS_WHBM0N3Y	PASJTA	19.87	NA	NA	01	TARGET	PASJTA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_FV0C303D	NA	PASJUU	NA	3	neutral	01	GMKF	PASJUU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASJUU-01A-01D	NA	PASJUU	NA	NA	NA	01	TARGET	PASJUU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASJWA-01A-01D	NA	PASJWA	NA	NA	NA	01	TARGET	PASJWA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_VGAKW5G6	NA	PASJWG	NA	3	gain	01	GMKF	PASJWG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASJWG-01A-01D	NA	PASJWG	NA	NA	NA	01	TARGET	PASJWG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASJWU-01A-01D	NA	PASJWU	NA	NA	NA	01	TARGET	PASJWU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PASJZC-01A-01R	PASJZC	35.63	NA	NA	01	TARGET	PASJZC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN non-amplified
BS_1YD0ZQ4R	NA	PASKCS	NA	NA	NA	01	GMKF	PASKCS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASKCS-01A-01D	NA	PASKCS	NA	NA	NA	01	TARGET	PASKCS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_JQ0XD1K9	BS_EE5Z0Z4J	PASKFM	50.58	NA	NA	01	GMKF	PASKFM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASKFV-01A-01D	NA	PASKFV	NA	3	gain	01	TARGET	PASKFV_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
BS_QDRHQSPZ	BS_6WBAV14H	PASKIS	334.3	3	gain	01	GMKF	PASKIS_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASKKZ-01A-01D	NA	PASKKZ	NA	NA	NA	01	TARGET	PASKKZ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASKNK-01A-01D	NA	PASKNK	NA	NA	NA	01	TARGET	PASKNK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASKPC-01A-01D	NA	PASKPC	NA	NA	NA	01	TARGET	PASKPC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASKRA-01A-01D	NA	PASKRA	NA	NA	NA	01	TARGET	PASKRA_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_W41Y820G	BS_QS2NKZW3	PASKRS	11.07	3	gain	01	GMKF	PASKRS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASKRS-01A-01D	BS_QS2NKZW3	PASKRS	11.07	NA	NA	01	TARGET	PASKRS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASKRX-01A-01D	NA	PASKRX	NA	NA	NA	01	TARGET	PASKRX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASKSR-01A-01D	NA	PASKSR	NA	NA	NA	01	TARGET	PASKSR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASKSX-01A-01D	NA	PASKSX	NA	NA	NA	01	TARGET	PASKSX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASKTB-01A-01D	NA	PASKTB	NA	2	loss	01	TARGET	PASKTB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	BS_3V34S6KM	PASKWI	0.86	NA	NA	01	GMKF	PASKWI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASKYH-01A-01D	NA	PASKYH	NA	NA	NA	01	TARGET	PASKYH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_CKVK1AYV	BS_CZ7DWCPE	PASKZT	2.05	NA	NA	01	GMKF	PASKZT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASKZT-01A-01D	BS_CZ7DWCPE	PASKZT	2.05	NA	NA	01	TARGET	PASKZT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASLAE-01A-01D	NA	PASLAE	NA	NA	NA	01	TARGET	PASLAE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASLCD-01A-01D	NA	PASLCD	NA	NA	NA	01	TARGET	PASLCD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASLDM-01A-01D	NA	PASLDM	NA	NA	NA	01	TARGET	PASLDM_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASLFG-01A-01D	NA	PASLFG	NA	NA	NA	01	TARGET	PASLFG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASLGM-01A-01D	NA	PASLGM	NA	NA	NA	01	TARGET	PASLGM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_6KH6CXMH	BS_HW9CGZ29	PASLIH	20.29	NA	NA	01	GMKF	PASLIH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASLIH-01A-01D	BS_HW9CGZ29	PASLIH	20.29	NA	NA	01	TARGET	PASLIH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_3CVTNBQ3	NA	PASLMN	NA	3	gain	01	GMKF	PASLMN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASLMN-01A-01D	NA	PASLMN	NA	NA	NA	01	TARGET	PASLMN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_V7B79J5R	BS_9C595Y9M	PASLPG	8.53	NA	NA	01	GMKF	PASLPG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASLPG-01A-01D	BS_9C595Y9M	PASLPG	8.53	NA	NA	01	TARGET	PASLPG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASLRM-01A-01D	NA	PASLRM	NA	NA	NA	01	TARGET	PASLRM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASLSS-01A-01D	NA	PASLSS	NA	NA	NA	01	TARGET	PASLSS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_AE718N55	BS_ZWRZRC4V	PASLTC	48.71	3	gain	01	GMKF	PASLTC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASLTC-01A-01D	BS_ZWRZRC4V	PASLTC	48.71	NA	NA	01	TARGET	PASLTC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_CPGZYTHM	NA	PASLTH	NA	NA	NA	01	GMKF	PASLTH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASLXS-01A-01D	NA	PASLXS	NA	NA	NA	01	TARGET	PASLXS_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASLYF-01A-01D	NA	PASLYF	NA	NA	NA	01	TARGET	PASLYF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASMCP-01A-01D	NA	PASMCP	NA	NA	NA	01	TARGET	PASMCP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASMDG-01A-01D	NA	PASMDG	NA	NA	NA	01	TARGET	PASMDG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PASMDM-01A-01R	PASMDM	37.6	NA	NA	01	TARGET	PASMDM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_RA5HNMDP	BS_0SC4QNTM	PASMET	86.26	46	amplification	01	GMKF	PASMET_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASMET-01A-01D	BS_0SC4QNTM	PASMET	86.26	NA	NA	01	TARGET	PASMET_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN non-amplified
BS_MJ2H7ZT3	BS_59ZF7365	PASMGS	28.29	3	loss	01	GMKF	PASMGS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_0RBGK29M	BS_KC02E200	PASMIU	48.41	3	gain	01	GMKF	PASMIU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASMJG-01A-01D	TARGET-30-PASMJG-01A-01R	PASMJG	1.73	2	neutral	01	TARGET	PASMJG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASMNT-01A-01D	TARGET-30-PASMNT-01A-01R	PASMNT	46.44	2	neutral	01	TARGET	PASMNT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASMNU-01A-01D	NA	PASMNU	NA	NA	NA	01	TARGET	PASMNU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASMPT-01A-01D	NA	PASMPT	NA	NA	NA	01	TARGET	PASMPT_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASMRC-01A-01D	NA	PASMRC	NA	NA	NA	01	TARGET	PASMRC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_69KVWAWK	BS_H5RWQDCJ	PASMUB	10.97	3	gain	01	GMKF	PASMUB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASMUB-01A-01D	BS_H5RWQDCJ	PASMUB	10.97	NA	NA	01	TARGET	PASMUB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASNEF-01A-01D	TARGET-30-PASNEF-01A-01R	PASNEF	33.26	2	loss	01	TARGET	PASNEF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_NVJJJ7MT	BS_WKPG4MH1	PASNHY	41.56	3	gain	01	GMKF	PASNHY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	BS_A3198WFE	PASNII	19.18	NA	NA	01	GMKF	PASNII_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASNMJ-01A-01D	NA	PASNMJ	NA	NA	NA	01	TARGET	PASNMJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PASNML-01A-01R	PASNML	72.94	NA	NA	01	TARGET	PASNML_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PASNPG-01A-01R	PASNPG	39	NA	NA	01	TARGET	PASNPG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PASNPG-02A-01R	PASNPG	24.6	NA	NA	02	TARGET	PASNPG_02_Solid Tissue_Recurrence	MYCN non-amp	NBL, MYCN non-amplified
BS_3564XTTK	BS_3CSY3JTN	PASNUI	407.97	647	amplification	01	GMKF	PASNUI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASNUI-01A-01D	BS_3CSY3JTN	PASNUI	407.97	NA	NA	01	TARGET	PASNUI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASNVM-01A-01D	NA	PASNVM	NA	NA	NA	01	TARGET	PASNVM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASNWH-01A-01D	NA	PASNWH	NA	NA	NA	01	TARGET	PASNWH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASNZU-01A-01D	TARGET-30-PASNZU-01A-01R	PASNZU	1052.53	152	amplification	01	TARGET	PASNZU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASPBY-01A-01D	NA	PASPBY	NA	NA	NA	01	TARGET	PASPBY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PASPBZ-01A-01R	PASPBZ	16.63	NA	NA	01	TARGET	PASPBZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASPER-01A-01D	TARGET-30-PASPER-01A-01R	PASPER	14.89	2	neutral	01	TARGET	PASPER_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASPGB-01A-01D	BS_94ZKC2SR	PASPGB	273.35	NA	NA	01	TARGET	PASPGB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_ACCE0MEA	BS_94ZKC2SR	PASPGB	273.35	3	gain	01	GMKF	PASPGB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASPGU-01A-01D	NA	PASPGU	NA	NA	NA	01	TARGET	PASPGU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASPIK-01A-01D	NA	PASPIK	NA	NA	NA	01	TARGET	PASPIK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_FK3DPAWA	NA	PASPIU	NA	NA	NA	01	GMKF	PASPIU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASPSE-01A-01D	NA	PASPSE	NA	NA	NA	01	TARGET	PASPSE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASPTF-01A-01D	NA	PASPTF	NA	NA	NA	01	TARGET	PASPTF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASPVR-09A-01D	NA	PASPVR	NA	NA	NA	09	TARGET	PASPVR_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASPVZ-09A-01D	NA	PASPVZ	NA	NA	NA	09	TARGET	PASPVZ_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASPXU-01A-01D	NA	PASPXU	NA	NA	NA	01	TARGET	PASPXU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_CH0ZV29W	NA	PASREV	NA	3	gain	09	GMKF	PASREV_09_Bone Marrow_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
BS_QCP0VAZ7	BS_6Y5F3QGV	PASREY	11.05	3	neutral	01	GMKF	PASREY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASRFS-01A-01D	TARGET-30-PASRFS-01A-01R	PASRFS	45.74	2	neutral	01	TARGET	PASRFS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASRIB-01A-01D	NA	PASRIB	NA	NA	NA	01	TARGET	PASRIB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASRLC-01A-01D	NA	PASRLC	NA	NA	NA	01	TARGET	PASRLC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_CD6KRB1K	BS_GWN2F333	PASRRY	25.98	3	gain	01	GMKF	PASRRY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASRSG-01A-01D	NA	PASRSG	NA	NA	NA	01	TARGET	PASRSG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_TS07B3TC	BS_5Z1QJPG6	PASRTR	58.98	3	gain	01	GMKF	PASRTR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_7ZT919XN	NA	PASRUT	NA	NA	NA	01	GMKF	PASRUT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASRWE-01A-01D	NA	PASRWE	NA	NA	NA	01	TARGET	PASRWE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASSEC-01A-01D	NA	PASSEC	NA	NA	NA	01	TARGET	PASSEC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_MQ6RKJCD	NA	PASSFD	NA	NA	NA	01	GMKF	PASSFD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASSGT-01A-01D	NA	PASSGT	NA	NA	NA	01	TARGET	PASSGT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASSII-01A-01D	NA	PASSII	NA	NA	NA	01	TARGET	PASSII_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASSJK-01A-01D	NA	PASSJK	NA	NA	NA	01	TARGET	PASSJK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_C9YD10Y4	BS_EXEE6TDK	PASSMV	7.74	NA	NA	01	GMKF	PASSMV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASSNN-01A-01D	NA	PASSNN	NA	NA	NA	01	TARGET	PASSNN_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASSPI-01A-01D	NA	PASSPI	NA	NA	NA	01	TARGET	PASSPI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASSRN-01A-01D	TARGET-30-PASSRN-01A-01R	PASSRN	738.94	522	amplification	01	TARGET	PASSRN_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASSRS-01A-01D	TARGET-30-PASSRS-01A-01R	PASSRS	18.08	2	loss	01	TARGET	PASSRS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASSUU-01A-01D	NA	PASSUU	NA	NA	NA	01	TARGET	PASSUU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASSWB-01A-01D	NA	PASSWB	NA	329	amplification	01	TARGET	PASSWB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_8S0EDFTP	BS_K9VNW7JD	PASSWW	9.37	NA	NA	01	GMKF	PASSWW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_8S0EDFTP	TARGET-30-PASSWW-01A-01R	PASSWW	17.69	NA	NA	01	GMKF	PASSWW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASSXA-01A-01D	NA	PASSXA	NA	NA	NA	01	TARGET	PASSXA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_X6BEG5J1	NA	PASSZI	NA	NA	NA	01	GMKF	PASSZI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASSZI-01A-01D	NA	PASSZI	NA	NA	NA	01	TARGET	PASSZI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASTCN-01A-01D	TARGET-30-PASTCN-01A-01R	PASTCN	36.66	2	loss	01	TARGET	PASTCN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASTDT-01A-01D	NA	PASTDT	NA	NA	NA	01	TARGET	PASTDT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASTGD-01A-01D	NA	PASTGD	NA	NA	NA	01	TARGET	PASTGD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASTGH-09A-01D	NA	PASTGH	NA	NA	NA	09	TARGET	PASTGH_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_CG9KDK95	NA	PASTHB	NA	NA	NA	01	GMKF	PASTHB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASTHF-01A-01D	NA	PASTHF	NA	NA	NA	01	TARGET	PASTHF_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASTIJ-01A-01D	NA	PASTIJ	NA	NA	NA	01	TARGET	PASTIJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASTKC-01A-01D	TARGET-30-PASTKC-01A-01R	PASTKC	24.11	2	loss	01	TARGET	PASTKC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASTKW-01A-01D	NA	PASTKW	NA	3	gain	01	TARGET	PASTKW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASTMW-09A-01D	NA	PASTMW	NA	NA	NA	09	TARGET	PASTMW_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASTNT-01A-01D	NA	PASTNT	NA	NA	NA	01	TARGET	PASTNT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_RQZZ6T97	BS_S01DMJ5X	PASTRD	3.16	NA	NA	01	GMKF	PASTRD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASTSI-01A-01D	NA	PASTSI	NA	NA	NA	01	TARGET	PASTSI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASTSY-01A-01D	NA	PASTSY	NA	NA	NA	01	TARGET	PASTSY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASTTX-01A-01D	NA	PASTTX	NA	NA	NA	01	TARGET	PASTTX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_MYVQ8YDT	NA	PASTVV	NA	NA	NA	01	GMKF	PASTVV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_A11S37GE	NA	PASTWV	NA	1	loss	01	GMKF	PASTWV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_C3KT9THS	BS_8EX2H96N	PASTWY	42.87	NA	NA	01	GMKF	PASTWY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASTWY-01A-01D	BS_8EX2H96N	PASTWY	42.87	NA	NA	01	TARGET	PASTWY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASTXR-01A-01D	NA	PASTXR	NA	2	loss	01	TARGET	PASTXR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASTXV-01A-01D	NA	PASTXV	NA	NA	NA	01	TARGET	PASTXV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_PS8TB6Z0	BS_HA1N9VCX	PASTZR	23.06	NA	NA	01	GMKF	PASTZR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASUCB-01A-01D	TARGET-30-PASUCB-01A-01R	PASUCB	11.22	2	loss	01	TARGET	PASUCB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_FAEHNS3Q	BS_4JVC08W2	PASUCU	26.41	3	gain	01	GMKF	PASUCU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASUCU-01A-01D	BS_4JVC08W2	PASUCU	26.41	NA	NA	01	TARGET	PASUCU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASUEA-01A-01D	NA	PASUEA	NA	NA	NA	01	TARGET	PASUEA_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_9ND96NYZ	BS_MDEQHB6J	PASUEZ	33.28	3	neutral	01	GMKF	PASUEZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASUEZ-01A-01D	BS_MDEQHB6J	PASUEZ	33.28	NA	NA	01	TARGET	PASUEZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_Y4V9JXG4	BS_2XTH5QRD	PASUFD	5.99	NA	NA	01	GMKF	PASUFD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASUFL-01A-01D	NA	PASUFL	NA	NA	NA	01	TARGET	PASUFL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_WSK7MH3C	NA	PASUMG	NA	122	amplification	01	GMKF	PASUMG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASUMG-01A-01D	NA	PASUMG	NA	NA	NA	01	TARGET	PASUMG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_9CPZ5R1T	BS_RW0JJ9BQ	PASUMK	0.6	NA	NA	01	GMKF	PASUMK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PASUML-01A-01R	PASUML	56.17	NA	NA	01	TARGET	PASUML_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASUTC-01A-01D	NA	PASUTC	NA	NA	NA	01	TARGET	PASUTC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_B80Z459E	NA	PASUTC	NA	4	neutral	01	GMKF	PASUTC_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
BS_9PRG9CJC	BS_MGHRCZEV	PASUVU	24.63	NA	NA	01	GMKF	PASUVU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASUXH-01A-01D	NA	PASUXH	NA	NA	NA	01	TARGET	PASUXH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASUYG-01A-01D	TARGET-30-PASUYG-01A-01R	PASUYG	7.84	3	neutral	01	TARGET	PASUYG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASUYL-01A-01D	NA	PASUYL	NA	NA	NA	01	TARGET	PASUYL_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_9G2RB0V8	NA	PASVCU	NA	NA	NA	01	GMKF	PASVCU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASVKE-01A-01D	NA	PASVKE	NA	NA	NA	01	TARGET	PASVKE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASVKL-09A-01D	NA	PASVKL	NA	NA	NA	09	TARGET	PASVKL_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASVRU-01A-01D	TARGET-30-PASVRU-01A-01R	PASVRU	473.38	121	amplification	01	TARGET	PASVRU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASVSU-09A-01D	NA	PASVSU	NA	NA	NA	09	TARGET	PASVSU_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASVWG-01A-01D	NA	PASVWG	NA	NA	NA	01	TARGET	PASVWG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_2SFR8Z1P	BS_8T0AKNMJ	PASVXS	9.01	NA	NA	01	GMKF	PASVXS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_QDMDQ3E3	BS_T4KS08ND	PASVYV	32.32	3	gain	01	GMKF	PASVYV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASVYV-01A-01D	BS_T4KS08ND	PASVYV	32.32	NA	NA	01	TARGET	PASVYV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASWAU-01A-01D	NA	PASWAU	NA	2	neutral	01	TARGET	PASWAU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASWCY-01A-01D	NA	PASWCY	NA	NA	NA	01	TARGET	PASWCY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_APY3G22J	BS_A70FPYSH	PASWEE	32.65	3	gain	01	GMKF	PASWEE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASWFB-01A-01D	TARGET-30-PASWFB-01A-01R	PASWFB	1034.06	195	amplification	01	TARGET	PASWFB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASWIJ-01A-01D	TARGET-30-PASWIJ-01A-01R	PASWIJ	57.63	3	neutral	01	TARGET	PASWIJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASWKI-01A-01D	NA	PASWKI	NA	NA	NA	01	TARGET	PASWKI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASWLY-01A-01D	NA	PASWLY	NA	2	loss	01	TARGET	PASWLY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_TT4PHFV7	BS_3CTRC269	PASWMY	13	NA	NA	01	GMKF	PASWMY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASWNG-01A-01D	NA	PASWNG	NA	NA	NA	01	TARGET	PASWNG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASWSZ-01A-01D	NA	PASWSZ	NA	NA	NA	01	TARGET	PASWSZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASWVD-01A-01D	NA	PASWVD	NA	NA	NA	01	TARGET	PASWVD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASWVE-01A-01D	NA	PASWVE	NA	NA	NA	01	TARGET	PASWVE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASWVY-01A-01D	TARGET-30-PASWVY-01A-01R	PASWVY	77.32	4	gain	01	TARGET	PASWVY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_R13WNSAR	BS_GMH5C45K	PASWXG	379.57	54	amplification	01	GMKF	PASWXG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASWXG-01A-01D	BS_GMH5C45K	PASWXG	379.57	NA	NA	01	TARGET	PASWXG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASWYR-01A-01D	BS_MPE34NYZ	PASWYR	368.45	138	amplification	01	TARGET	PASWYR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASWYR-01A-01D	TARGET-30-PASWYR-01A-01R	PASWYR	1027.81	138	amplification	01	TARGET	PASWYR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_8XDZQKSD	NA	PASWYR	NA	3	gain	01	GMKF	PASWYR_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
TARGET-30-PASXCG-01A-01D	NA	PASXCG	NA	NA	NA	01	TARGET	PASXCG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASXGP-01A-01D	TARGET-30-PASXGP-01A-01R	PASXGP	53.89	2	neutral	01	TARGET	PASXGP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_V4VGG98Y	BS_EZRVK9ZQ	PASXHE	33.44	3	gain	01	GMKF	PASXHE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_V4VGG98Y	TARGET-30-PASXHE-01A-01R	PASXHE	74.93	3	gain	01	GMKF	PASXHE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASXHE-01A-01D	BS_EZRVK9ZQ	PASXHE	33.44	3	gain	01	TARGET	PASXHE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASXHE-01A-01D	TARGET-30-PASXHE-01A-01R	PASXHE	74.93	3	gain	01	TARGET	PASXHE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_2N95EW0G	BS_9TKGBJH7	PASXIE	548.93	6	gain	01	GMKF	PASXIE_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_2N95EW0G	TARGET-30-PASXIE-01A-01R	PASXIE	1258.74	6	gain	01	GMKF	PASXIE_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASXIE-01A-01D	NA	PASXIE	NA	3	gain	01	TARGET	PASXIE_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
TARGET-30-PASXMI-09A-01D	NA	PASXMI	NA	NA	NA	09	TARGET	PASXMI_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASXNN-01A-01D	NA	PASXNN	NA	2	loss	01	TARGET	PASXNN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_P6FPBJM8	NA	PASXRG	NA	NA	NA	01	GMKF	PASXRG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASXRG-01A-01D	BS_9JBYGRQW	PASXRG	181.71	14	amplification	01	TARGET	PASXRG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASXRG-01A-01D	TARGET-30-PASXRG-01A-01R	PASXRG	285.66	14	amplification	01	TARGET	PASXRG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_KXRFQF5N	NA	PASXRJ	NA	NA	NA	01	GMKF	PASXRJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASXRJ-01A-01D	BS_1BKHK7AY	PASXRJ	14.24	2	neutral	01	TARGET	PASXRJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASXRJ-01A-01D	TARGET-30-PASXRJ-01A-01R	PASXRJ	34.46	2	neutral	01	TARGET	PASXRJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_9ZDR2H7D	BS_XZQE9FBM	PASXSJ	261.14	106	amplification	01	GMKF	PASXSJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_4G4PK2D4	NA	PASXVW	NA	3	loss	01	GMKF	PASXVW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_SPGHWHXY	BS_CD6WEHG9	PASXWF	2.17	NA	NA	01	GMKF	PASXWF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_H68W3CE8	NA	PASYHS	NA	3	gain	01	GMKF	PASYHS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_XH6P7BY8	NA	PASYIP	NA	99	amplification	01	GMKF	PASYIP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASYIP-01A-01D	NA	PASYIP	NA	NA	NA	01	TARGET	PASYIP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_SGRCCAVT	NA	PASYJF	NA	3	gain	01	GMKF	PASYJF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASYJF-01A-01D	NA	PASYJF	NA	NA	NA	01	TARGET	PASYJF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASYLD-01A-01D	NA	PASYLD	NA	2	neutral	01	TARGET	PASYLD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASYMX-01A-01D	NA	PASYMX	NA	3	loss	01	TARGET	PASYMX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASYPX-01A-01D	TARGET-30-PASYPX-01A-01R	PASYPX	31.64	3	neutral	01	TARGET	PASYPX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASYTP-01A-01D	NA	PASYTP	NA	NA	NA	01	TARGET	PASYTP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_B4GBBM0J	NA	PASYVV	NA	NA	NA	01	GMKF	PASYVV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASYYM-01A-01D	NA	PASYYM	NA	NA	NA	01	TARGET	PASYYM_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PASYYX-01A-01D	NA	PASYYX	NA	NA	NA	01	TARGET	PASYYX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_XQSEQPAZ	BS_EPZ2H50J	PASYYZ	1.27	NA	NA	01	GMKF	PASYYZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASZFX-01A-01D	NA	PASZFX	NA	NA	NA	01	TARGET	PASZFX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PASZGB-01A-01D	NA	PASZGB	NA	NA	NA	01	TARGET	PASZGB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_ZRG2V7T2	BS_CXGWN1W5	PASZJB	18.88	3	loss	01	GMKF	PASZJB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASZJB-01A-01D	BS_CXGWN1W5	PASZJB	18.88	NA	NA	01	TARGET	PASZJB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	BS_XPTREBJD	PASZKE	11.37	NA	NA	01	GMKF	PASZKE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PASZKE-01A-01R	PASZKE	20.97	NA	NA	01	TARGET	PASZKE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASZPI-01A-01D	TARGET-30-PASZPI-01A-01R	PASZPI	894.63	44	amplification	01	TARGET	PASZPI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_Y9BHAPG3	BS_FRY5NFRY	PASZRF	17.59	NA	NA	01	GMKF	PASZRF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASZST-01A-01D	NA	PASZST	NA	NA	NA	01	TARGET	PASZST_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_DGV11G69	BS_RZEEJETF	PASZTC	19.89	3	gain	01	GMKF	PASZTC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PASZTV-01A-01D	NA	PASZTV	NA	NA	NA	01	TARGET	PASZTV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_BHKAK446	NA	PASZYY	NA	203	amplification	01	GMKF	PASZYY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PASZYY-01A-01D	NA	PASZYY	NA	NA	NA	01	TARGET	PASZYY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_PKHXM1NB	BS_XJDB3R9K	PATAAV	8.73	3	gain	01	GMKF	PATAAV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATAAV-01A-01D	BS_XJDB3R9K	PATAAV	8.73	NA	NA	01	TARGET	PATAAV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATACA-01A-01D	NA	PATACA	NA	NA	NA	01	TARGET	PATACA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATAFE-01A-01D	NA	PATAFE	NA	NA	NA	01	TARGET	PATAFE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATAFI-01A-01D	NA	PATAFI	NA	NA	NA	01	TARGET	PATAFI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATAKH-01A-01D	NA	PATAKH	NA	NA	NA	01	TARGET	PATAKH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PATAYJ-01A-01R	PATAYJ	40.96	NA	NA	01	TARGET	PATAYJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATBAC-01A-01D	NA	PATBAC	NA	NA	NA	01	TARGET	PATBAC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_S0T1WT6R	NA	PATBBF	NA	3	gain	01	GMKF	PATBBF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_W09W6AAS	BS_FE3BY6DT	PATBCM	5.2	NA	NA	01	GMKF	PATBCM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_HCWEF4QN	BS_Z3BZ01S1	PATBFN	33.83	NA	NA	01	GMKF	PATBFN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_7W42FH5A	BS_M462FWS9	PATBGF	6.68	NA	NA	01	GMKF	PATBGF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATBHY-01A-01D	BS_NQP7B1SY	PATBHY	16.32	NA	NA	01	TARGET	PATBHY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATBJI-01A-01D	NA	PATBJI	NA	NA	NA	01	TARGET	PATBJI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATBKX-01A-01D	NA	PATBKX	NA	NA	NA	01	TARGET	PATBKX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_7S8KSFRC	NA	PATBLZ	NA	NA	NA	01	GMKF	PATBLZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_D7442ACV	NA	PATBMM	NA	NA	NA	01	GMKF	PATBMM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATBMM-01A-01D	BS_3DJBSNGE	PATBMM	12.3	2	loss	01	TARGET	PATBMM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATBMM-01A-01D	TARGET-30-PATBMM-01A-01R	PATBMM	15.49	2	loss	01	TARGET	PATBMM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATBPG-01A-01D	NA	PATBPG	NA	NA	NA	01	TARGET	PATBPG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATBRX-01A-01D	NA	PATBRX	NA	NA	NA	01	TARGET	PATBRX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATCDJ-01A-01D	NA	PATCDJ	NA	NA	NA	01	TARGET	PATCDJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATCEM-01A-01D	NA	PATCEM	NA	NA	NA	01	TARGET	PATCEM_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_D3N3FG7Y	NA	PATCFL	NA	NA	NA	01	GMKF	PATCFL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATCFL-01A-01D	BS_N05R3CT2	PATCFL	3.24	2	neutral	01	TARGET	PATCFL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATCFL-01A-01D	TARGET-30-PATCFL-01A-01R	PATCFL	6.9	2	neutral	01	TARGET	PATCFL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATCJF-01A-01D	NA	PATCJF	NA	NA	NA	01	TARGET	PATCJF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATCJP-09A-01D	NA	PATCJP	NA	NA	NA	09	TARGET	PATCJP_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATCKU-01A-01D	NA	PATCKU	NA	NA	NA	01	TARGET	PATCKU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
NA	BS_MYNJDVWV	PATCMD	43.2	NA	NA	01	GMKF	PATCMD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_F92J3KBA	BS_JWXQFZY9	PATCVK	15.78	NA	NA	01	GMKF	PATCVK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATDBR-01A-01D	NA	PATDBR	NA	NA	NA	01	TARGET	PATDBR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_DZ998H9P	BS_BBD7XS5N	PATDCJ	13.3	3	gain	01	GMKF	PATDCJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATDCJ-01A-01D	BS_BBD7XS5N	PATDCJ	13.3	NA	NA	01	TARGET	PATDCJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATDFU-01A-01D	NA	PATDFU	NA	NA	NA	01	TARGET	PATDFU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_TWN989ZD	BS_YF5NCTGA	PATDKL	3.77	NA	NA	01	GMKF	PATDKL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATDSY-01A-01D	NA	PATDSY	NA	NA	NA	01	TARGET	PATDSY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATDVF-01A-01D	NA	PATDVF	NA	NA	NA	01	TARGET	PATDVF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATDWN-01A-01D	TARGET-30-PATDWN-01A-01R	PATDWN	1540.66	238	amplification	01	TARGET	PATDWN_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_XWKDJ2M6	BS_4A1CKAXN	PATDWR	15.89	NA	NA	01	GMKF	PATDWR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATDXC-01A-01D	TARGET-30-PATDXC-01A-01R	PATDXC	58.6	3	neutral	01	TARGET	PATDXC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATDXG-01A-01D	TARGET-30-PATDXG-01A-01R	PATDXG	1449.04	118	amplification	01	TARGET	PATDXG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATECM-01A-01D	NA	PATECM	NA	NA	NA	01	TARGET	PATECM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_WFZG82XZ	BS_XFFQR05Z	PATEEE	8.55	NA	NA	01	GMKF	PATEEE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATEKG-01A-01D	TARGET-30-PATEKG-01A-01R	PATEKG	5.33	2	neutral	01	TARGET	PATEKG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATEPF-01A-01D	TARGET-30-PATEPF-01A-01R	PATEPF	40.48	2	neutral	01	TARGET	PATEPF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATESI-01A-01D	TARGET-30-PATESI-01A-01R	PATESI	1278.85	105	amplification	01	TARGET	PATESI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_K5DHTP34	BS_3GRJH3PS	PATETW	17.35	NA	NA	01	GMKF	PATETW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATEUC-01A-01D	NA	PATEUC	NA	NA	NA	01	TARGET	PATEUC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATEWM-01A-01D	NA	PATEWM	NA	NA	NA	01	TARGET	PATEWM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATFCY-01A-01D	TARGET-30-PATFCY-01A-01R	PATFCY	60.56	2	loss	01	TARGET	PATFCY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATFES-01A-01D	NA	PATFES	NA	NA	NA	01	TARGET	PATFES_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_64P50TAP	BS_CZMY8CVE	PATFIK	41.21	3	gain	01	GMKF	PATFIK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATFIN-01A-01D	NA	PATFIN	NA	128	amplification	01	TARGET	PATFIN_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATFMU-01A-01D	NA	PATFMU	NA	NA	NA	01	TARGET	PATFMU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_2F5KDZ93	NA	PATFPK	NA	NA	NA	09	GMKF	PATFPK_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATFPS-09A-01D	NA	PATFPS	NA	NA	NA	09	TARGET	PATFPS_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATFTN-01A-01D	NA	PATFTN	NA	NA	NA	01	TARGET	PATFTN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_XQC9PNZP	BS_GTFHNG3R	PATFTR	27.57	NA	NA	01	GMKF	PATFTR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATFTR-01A-01D	BS_GTFHNG3R	PATFTR	27.57	NA	NA	01	TARGET	PATFTR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATFTY-01A-01D	NA	PATFTY	NA	NA	NA	01	TARGET	PATFTY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATFXV-01A-01D	TARGET-30-PATFXV-01A-01R	PATFXV	1554.55	188	amplification	01	TARGET	PATFXV_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_VKK21QBZ	BS_JBKQ59CW	PATGIW	6.43	NA	NA	01	GMKF	PATGIW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PATGJU-01A-01R	PATGJU	26.34	NA	NA	01	TARGET	PATGJU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_2P6MH05V	TARGET-30-PATGLU-01A-01R	PATGLU	50.36	3	gain	01	GMKF	PATGLU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATGLU-01A-01D	TARGET-30-PATGLU-01A-01R	PATGLU	50.36	3	gain	01	TARGET	PATGLU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATGWT-01A-01D	NA	PATGWT	NA	129	amplification	01	TARGET	PATGWT_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATGWU-01A-01D	NA	PATGWU	NA	NA	NA	01	TARGET	PATGWU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATHJU-09A-01D	NA	PATHJU	NA	NA	NA	09	TARGET	PATHJU_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
BS_89V49XKJ	NA	PATHJZ	NA	3	gain	01	GMKF	PATHJZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATHJZ-01A-01D	NA	PATHJZ	NA	NA	NA	01	TARGET	PATHJZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PATHKB-01A-01R	PATHKB	88.44	NA	NA	01	TARGET	PATHKB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATHUU-01A-01D	NA	PATHUU	NA	NA	NA	01	TARGET	PATHUU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATHVK-01A-01D	TARGET-30-PATHVK-01A-01R	PATHVK	25.72	4	neutral	01	TARGET	PATHVK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_JXVVZ2S8	NA	PATHYD	NA	3	gain	01	GMKF	PATHYD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATHYK-01A-01D	NA	PATHYK	NA	NA	NA	01	TARGET	PATHYK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATIHB-01A-01D	NA	PATIHB	NA	NA	NA	01	TARGET	PATIHB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_GFN4FETJ	BS_2480EHNY	PATIIT	42.43	NA	NA	01	GMKF	PATIIT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATILE-01A-01D	NA	PATILE	NA	2	loss	01	TARGET	PATILE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATINJ-01A-01D	TARGET-30-PATINJ-01A-01R	PATINJ	52.26	2	neutral	01	TARGET	PATINJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_WCEHT7D0	BS_NR090DDV	PATIRK	6.42	NA	NA	01	GMKF	PATIRK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATISU-01A-01D	NA	PATISU	NA	NA	NA	01	TARGET	PATISU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATIWH-01A-01D	NA	PATIWH	NA	NA	NA	01	TARGET	PATIWH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATIYD-09A-01D	NA	PATIYD	NA	NA	NA	09	TARGET	PATIYD_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
BS_E4V8XN3G	NA	PATIYD	NA	3	gain	09	GMKF	PATIYD_09_Bone Marrow_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
BS_H915DJY3	NA	PATIYR	NA	NA	NA	01	GMKF	PATIYR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_JZFMHGNX	BS_ETC8R0TD	PATJDG	1.7	NA	NA	01	GMKF	PATJDG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATJET-01A-01D	NA	PATJET	NA	NA	NA	01	TARGET	PATJET_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATJEY-01A-01D	NA	PATJEY	NA	NA	NA	01	TARGET	PATJEY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_7NXB23C9	NA	PATJGB	NA	3	gain	01	GMKF	PATJGB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATJHU-01A-01D	NA	PATJHU	NA	NA	NA	01	TARGET	PATJHU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATJIN-01A-01D	NA	PATJIN	NA	NA	NA	01	TARGET	PATJIN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_T62SHZA7	NA	PATJIV	NA	NA	NA	01	GMKF	PATJIV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATJPI-01A-01D	NA	PATJPI	NA	NA	NA	01	TARGET	PATJPI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATJXV-01A-01D	NA	PATJXV	NA	NA	NA	01	TARGET	PATJXV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATJZC-01A-01D	NA	PATJZC	NA	NA	NA	01	TARGET	PATJZC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATJZF-01A-01D	NA	PATJZF	NA	NA	NA	01	TARGET	PATJZF_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_YK9W04XG	BS_9BYP1GZS	PATKGB	40.95	3	loss	01	GMKF	PATKGB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATKGB-01A-01D	BS_9BYP1GZS	PATKGB	40.95	NA	NA	01	TARGET	PATKGB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATKHS-01A-01D	NA	PATKHS	NA	NA	NA	01	TARGET	PATKHS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATKPD-01A-01D	NA	PATKPD	NA	NA	NA	01	TARGET	PATKPD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_4WSW3X49	NA	PATKPD	NA	3	gain	01	GMKF	PATKPD_01_Solid Tissue_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
TARGET-30-PATKSX-01A-01D	NA	PATKSX	NA	NA	NA	01	TARGET	PATKSX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_38SSRZJ1	BS_Y2DSNJ1E	PATLBP	14.18	NA	NA	01	GMKF	PATLBP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATLCM-01A-01D	NA	PATLCM	NA	NA	NA	01	TARGET	PATLCM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_WRZATZQF	BS_JFJYEHFM	PATLFF	18.12	3	gain	01	GMKF	PATLFF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_3AKS23A0	BS_F2F7BXT5	PATLFX	26.59	3	gain	01	GMKF	PATLFX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATLKI-01A-01D	BS_QJ3XB7XZ	PATLKI	29.28	NA	NA	01	TARGET	PATLKI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN non-amplified
BS_A5AQFAFA	BS_QJ3XB7XZ	PATLKI	29.28	3	gain	01	GMKF	PATLKI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN non-amplified
TARGET-30-PATLLI-01A-01D	NA	PATLLI	NA	NA	NA	01	TARGET	PATLLI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATLNM-01A-01D	NA	PATLNM	NA	NA	NA	01	TARGET	PATLNM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_4VKRBRJC	BS_F9ZXCH60	PATLSY	3.7	NA	NA	01	GMKF	PATLSY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATLUI-01A-01D	NA	PATLUI	NA	NA	NA	01	TARGET	PATLUI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATLXP-01A-01D	NA	PATLXP	NA	NA	NA	01	TARGET	PATLXP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATMAJ-01A-01D	NA	PATMAJ	NA	NA	NA	01	TARGET	PATMAJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATMAW-01A-01D	NA	PATMAW	NA	NA	NA	01	TARGET	PATMAW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_BPXHZ3Y0	BS_5W25GMQ1	PATMDE	2.09	NA	NA	01	GMKF	PATMDE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_H7T26DMD	NA	PATMFH	NA	NA	NA	01	GMKF	PATMFH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATMFL-01A-01D	NA	PATMFL	NA	NA	NA	01	TARGET	PATMFL_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATMJV-09A-01D	NA	PATMJV	NA	NA	NA	09	TARGET	PATMJV_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATMPC-01A-01D	NA	PATMPC	NA	NA	NA	01	TARGET	PATMPC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_1GQJVG9Q	NA	PATMRZ	NA	NA	NA	01	GMKF	PATMRZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATMRZ-01A-01D	NA	PATMRZ	NA	NA	NA	01	TARGET	PATMRZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATMSI-01A-01D	NA	PATMSI	NA	NA	NA	01	TARGET	PATMSI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATMSR-01A-01D	NA	PATMSR	NA	NA	NA	01	TARGET	PATMSR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATMTX-01A-01D	NA	PATMTX	NA	NA	NA	01	TARGET	PATMTX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_4J4MVGTR	NA	PATMVN	NA	NA	NA	01	GMKF	PATMVN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATMXC-01A-01D	NA	PATMXC	NA	NA	NA	01	TARGET	PATMXC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_35DBPYMN	NA	PATMZJ	NA	NA	NA	01	GMKF	PATMZJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_SXVVN52M	NA	PATNBK	NA	3	gain	01	GMKF	PATNBK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATNCI-01A-01D	NA	PATNCI	NA	NA	NA	01	TARGET	PATNCI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_8DB19DYW	NA	PATNEA	NA	3	gain	01	GMKF	PATNEA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATNEA-01A-01D	NA	PATNEA	NA	NA	NA	01	TARGET	PATNEA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATNGD-01A-01D	NA	PATNGD	NA	NA	NA	01	TARGET	PATNGD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PATNKP-02A-01R	PATNKP	35.73	NA	NA	02	TARGET	PATNKP_02_Solid Tissue_Recurrence	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATNPW-01A-01D	NA	PATNPW	NA	NA	NA	01	TARGET	PATNPW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATNRI-01A-01D	NA	PATNRI	NA	NA	NA	01	TARGET	PATNRI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATNRK-09A-01D	NA	PATNRK	NA	NA	NA	09	TARGET	PATNRK_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
BS_NK1FJNRG	BS_XHSRBERM	PATNUK	11.42	NA	NA	01	GMKF	PATNUK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_S4R97RNZ	BS_KYGRX01W	PATNVA	12.14	NA	NA	01	GMKF	PATNVA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATNWL-01A-01D	NA	PATNWL	NA	NA	NA	01	TARGET	PATNWL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_R0WH31Q0	BS_HEKMP7BH	PATNWM	22.37	NA	NA	01	GMKF	PATNWM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_GAA781GQ	BS_MH01GQ2B	PATNXJ	28.29	NA	NA	01	GMKF	PATNXJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_6FA0NNF1	BS_S0SM38BZ	PATNXK	23.59	NA	NA	01	GMKF	PATNXK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATNXK-01A-01D	BS_S0SM38BZ	PATNXK	23.59	NA	NA	01	TARGET	PATNXK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_4D9SK48F	NA	PATNZJ	NA	75	amplification	01	GMKF	PATNZJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATNZJ-01A-01D	NA	PATNZJ	NA	NA	NA	01	TARGET	PATNZJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_P9FWPEYY	NA	PATNZR	NA	NA	NA	01	GMKF	PATNZR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATPET-01A-01D	NA	PATPET	NA	NA	NA	01	TARGET	PATPET_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_9PEJSEZG	BS_AYDD070S	PATPFG	22.7	3	gain	01	GMKF	PATPFG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATPHR-01A-01D	NA	PATPHR	NA	NA	NA	01	TARGET	PATPHR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_ZYXTC212	NA	PATPIU	NA	NA	NA	01	GMKF	PATPIU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATPJD-09A-01D	NA	PATPJD	NA	NA	NA	09	TARGET	PATPJD_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATPNR-01A-01D	NA	PATPNR	NA	NA	NA	01	TARGET	PATPNR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATPPK-01A-01D	NA	PATPPK	NA	NA	NA	01	TARGET	PATPPK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATPPU-01A-01D	NA	PATPPU	NA	NA	NA	01	TARGET	PATPPU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_T9KJYH7M	BS_8NQWYZHR	PATPPY	20.82	NA	NA	01	GMKF	PATPPY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_EE2YW499	NA	PATPXF	NA	NA	NA	01	GMKF	PATPXF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATPXF-01A-01D	NA	PATPXF	NA	NA	NA	01	TARGET	PATPXF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATPXJ-01A-01D	NA	PATPXJ	NA	NA	NA	01	TARGET	PATPXJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATPYK-01A-01D	NA	PATPYK	NA	NA	NA	01	TARGET	PATPYK_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATRHD-01A-01D	NA	PATRHD	NA	NA	NA	01	TARGET	PATRHD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATRJG-01A-01D	NA	PATRJG	NA	NA	NA	01	TARGET	PATRJG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATRJK-01A-01D	NA	PATRJK	NA	NA	NA	01	TARGET	PATRJK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATRMB-01A-01D	NA	PATRMB	NA	NA	NA	01	TARGET	PATRMB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_CP8741SX	NA	PATRNL	NA	3	gain	01	GMKF	PATRNL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATRUL-01A-01D	NA	PATRUL	NA	NA	NA	01	TARGET	PATRUL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATRUX-09A-01D	NA	PATRUX	NA	NA	NA	09	TARGET	PATRUX_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
BS_WSD8PV27	NA	PATRVB	NA	NA	NA	01	GMKF	PATRVB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATRXC-01A-01D	NA	PATRXC	NA	NA	NA	01	TARGET	PATRXC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_55PH1SAS	NA	PATRZM	NA	4	gain	01	GMKF	PATRZM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_BF83XX7P	NA	PATSCT	NA	3	gain	01	GMKF	PATSCT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATSDR-01A-01D	NA	PATSDR	NA	NA	NA	01	TARGET	PATSDR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_K9P9N35B	NA	PATSEC	NA	NA	NA	09	GMKF	PATSEC_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_X3AFTRNM	BS_DERH44Z2	PATSIJ	19.48	NA	NA	01	GMKF	PATSIJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATSJV-01A-01D	NA	PATSJV	NA	NA	NA	01	TARGET	PATSJV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATSKE-01A-01D	NA	PATSKE	NA	NA	NA	01	TARGET	PATSKE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_FXG6F3NN	BS_WKC3GR0D	PATSNC	8.33	NA	NA	01	GMKF	PATSNC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATSPZ-01A-01D	NA	PATSPZ	NA	NA	NA	01	TARGET	PATSPZ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATSRD-01A-01D	NA	PATSRD	NA	NA	NA	01	TARGET	PATSRD_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_K62HBS01	BS_WFCVBVDS	PATSRY	29.52	3	loss	01	GMKF	PATSRY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_XDH1Y1TQ	NA	PATSSA	NA	NA	NA	01	GMKF	PATSSA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATSSA-01A-01D	NA	PATSSA	NA	NA	NA	01	TARGET	PATSSA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_P69A72G2	NA	PATSSG	NA	3	gain	01	GMKF	PATSSG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_255803B6	BS_3D1XTG0K	PATSTU	4.33	NA	NA	01	GMKF	PATSTU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_QZAV7XVF	BS_NN42N0XB	PATSUB	24.04	3	gain	01	GMKF	PATSUB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_ACDQRWMY	BS_MG1N76FY	PATSUL	8.57	NA	NA	01	GMKF	PATSUL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_CQ40NN4X	NA	PATSVA	NA	23	amplification	01	GMKF	PATSVA_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATSXC-01A-01D	NA	PATSXC	NA	NA	NA	01	TARGET	PATSXC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_NB0ESCXK	NA	PATTCU	NA	NA	NA	01	GMKF	PATTCU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_HEP8QTNN	NA	PATTDY	NA	NA	NA	01	GMKF	PATTDY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATTDY-01A-01D	NA	PATTDY	NA	NA	NA	01	TARGET	PATTDY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATTEF-01A-01D	NA	PATTEF	NA	NA	NA	01	TARGET	PATTEF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATTFB-01A-01D	NA	PATTFB	NA	NA	NA	01	TARGET	PATTFB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_WVMWHF4P	NA	PATTFS	NA	NA	NA	01	GMKF	PATTFS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATTHA-01A-01D	NA	PATTHA	NA	NA	NA	01	TARGET	PATTHA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_B2RYV4GG	BS_S32M2YTY	PATTHB	25.6	3	gain	01	GMKF	PATTHB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATTMM-01A-01D	NA	PATTMM	NA	NA	NA	01	TARGET	PATTMM_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATTNA-01A-01D	NA	PATTNA	NA	NA	NA	01	TARGET	PATTNA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_G4W213NW	BS_DHXNWXP6	PATTNX	36.26	3	gain	01	GMKF	PATTNX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_GBS4JMAZ	BS_NKGRBE18	PATTPC	393.89	244	amplification	01	GMKF	PATTPC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATTPC-01A-01D	BS_NKGRBE18	PATTPC	393.89	NA	NA	01	TARGET	PATTPC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATTPL-01A-01D	NA	PATTPL	NA	NA	NA	01	TARGET	PATTPL_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATTPW-01A-01D	NA	PATTPW	NA	NA	NA	01	TARGET	PATTPW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_ABZC437A	NA	PATTTS	NA	NA	NA	01	GMKF	PATTTS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_D9BP1QN2	NA	PATTWT	NA	NA	NA	01	GMKF	PATTWT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_XX68G6KE	NA	PATUAI	NA	NA	NA	01	GMKF	PATUAI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_E4N511ZX	BS_E359X3QV	PATUBI	26.85	NA	NA	01	GMKF	PATUBI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATUEH-01A-01D	NA	PATUEH	NA	NA	NA	01	TARGET	PATUEH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATUNK-01A-01D	NA	PATUNK	NA	NA	NA	01	TARGET	PATUNK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATUNX-01A-01D	NA	PATUNX	NA	NA	NA	01	TARGET	PATUNX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATUNZ-01A-01D	NA	PATUNZ	NA	NA	NA	01	TARGET	PATUNZ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_NNH2A86D	BS_10MQQC5C	PATUPN	13.36	NA	NA	01	GMKF	PATUPN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATUPR-09A-01D	NA	PATUPR	NA	NA	NA	09	TARGET	PATUPR_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATUVB-01A-01D	NA	PATUVB	NA	NA	NA	01	TARGET	PATUVB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_STK02B14	NA	PATUWG	NA	3	loss	01	GMKF	PATUWG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATUWG-01A-01D	NA	PATUWG	NA	NA	NA	01	TARGET	PATUWG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATUZF-01A-01D	NA	PATUZF	NA	NA	NA	01	TARGET	PATUZF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATVDI-01A-01D	NA	PATVDI	NA	NA	NA	01	TARGET	PATVDI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATVDP-01A-01D	NA	PATVDP	NA	NA	NA	01	TARGET	PATVDP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATVDY-09A-01D	NA	PATVDY	NA	NA	NA	09	TARGET	PATVDY_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
BS_SYQG48V0	NA	PATVER	NA	NA	NA	01	GMKF	PATVER_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_EDGSP4V6	BS_8GD69HHF	PATVHJ	16.33	NA	NA	01	GMKF	PATVHJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATVJX-01A-01D	NA	PATVJX	NA	NA	NA	01	TARGET	PATVJX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_0Y4VHCMS	NA	PATVKG	NA	NA	NA	01	GMKF	PATVKG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_6S50RDHT	NA	PATVKI	NA	3	gain	01	GMKF	PATVKI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_6AENZKKA	BS_Z36F6GKX	PATVKN	11.39	NA	NA	01	GMKF	PATVKN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_8JTH2X5Z	NA	PATVMF	NA	NA	NA	01	GMKF	PATVMF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATVMF-01A-01D	NA	PATVMF	NA	NA	NA	01	TARGET	PATVMF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATVNW-01A-01D	NA	PATVNW	NA	NA	NA	01	TARGET	PATVNW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_YPKSF86W	BS_83RF7CY6	PATVRG	11.96	3	gain	01	GMKF	PATVRG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATVSU-01A-01D	NA	PATVSU	NA	NA	NA	01	TARGET	PATVSU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATVTL-01A-01D	NA	PATVTL	NA	NA	NA	01	TARGET	PATVTL_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_PDWEETXG	NA	PATVVB	NA	3	gain	01	GMKF	PATVVB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATVWA-01A-01D	NA	PATVWA	NA	NA	NA	01	TARGET	PATVWA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_NGBKDYFB	NA	PATVYZ	NA	NA	NA	01	GMKF	PATVYZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATVYZ-01A-01D	NA	PATVYZ	NA	NA	NA	01	TARGET	PATVYZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATVZB-01A-01D	NA	PATVZB	NA	NA	NA	01	TARGET	PATVZB_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_SSS5J8P5	NA	PATWAG	NA	3	gain	09	GMKF	PATWAG_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_588QYDB1	NA	PATWDV	NA	3	loss	01	GMKF	PATWDV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_HZKJMB0D	BS_YA56YE71	PATWED	82.09	29	amplification	01	GMKF	PATWED_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATWED-01A-01D	BS_YA56YE71	PATWED	82.09	NA	NA	01	TARGET	PATWED_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN non-amplified
BS_QNQDTDCS	NA	PATWEJ	NA	3	gain	01	GMKF	PATWEJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATWGC-01A-01D	NA	PATWGC	NA	NA	NA	01	TARGET	PATWGC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_1FR8GJ7N	NA	PATWGR	NA	188	amplification	01	GMKF	PATWGR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATWGR-01A-01D	NA	PATWGR	NA	NA	NA	01	TARGET	PATWGR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_R66Z3ENM	BS_KBXSSXWF	PATWIL	19.1	NA	NA	01	GMKF	PATWIL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATWIL-01A-01D	BS_KBXSSXWF	PATWIL	19.1	NA	NA	01	TARGET	PATWIL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATWMX-01A-01D	NA	PATWMX	NA	NA	NA	01	TARGET	PATWMX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATWNB-01A-01D	NA	PATWNB	NA	NA	NA	01	TARGET	PATWNB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_25EXB29C	BS_8V59CEJJ	PATWPC	10.85	NA	NA	01	GMKF	PATWPC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_7HRQNWJY	BS_STTGK8V4	PATWPL	34.48	3	neutral	01	GMKF	PATWPL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_YTQ6Y7FQ	NA	PATWTJ	NA	NA	NA	01	GMKF	PATWTJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATWTW-01A-01D	NA	PATWTW	NA	NA	NA	01	TARGET	PATWTW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATWWJ-01A-01D	NA	PATWWJ	NA	NA	NA	01	TARGET	PATWWJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATWZB-01A-01D	NA	PATWZB	NA	NA	NA	01	TARGET	PATWZB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATWZZ-01A-01D	NA	PATWZZ	NA	NA	NA	01	TARGET	PATWZZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATXDV-01A-01D	NA	PATXDV	NA	NA	NA	01	TARGET	PATXDV_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_J8YAY1HM	NA	PATXGG	NA	NA	NA	01	GMKF	PATXGG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_E7CRT00M	NA	PATXHB	NA	NA	NA	01	GMKF	PATXHB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATXHC-01A-01D	NA	PATXHC	NA	NA	NA	01	TARGET	PATXHC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATXHT-01A-01D	NA	PATXHT	NA	NA	NA	01	TARGET	PATXHT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATXHW-01A-01D	NA	PATXHW	NA	NA	NA	01	TARGET	PATXHW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_01BDZ0TW	NA	PATXKG	NA	31	amplification	01	GMKF	PATXKG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATXKG-01A-01D	NA	PATXKG	NA	NA	NA	01	TARGET	PATXKG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_SMJRCVQB	BS_0D3SCV7P	PATXKN	9.08	3	gain	01	GMKF	PATXKN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_76SQJSHP	BS_BW9QBKEQ	PATXTF	36.56	5	gain	01	GMKF	PATXTF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATXTF-01A-01D	BS_BW9QBKEQ	PATXTF	36.56	NA	NA	01	TARGET	PATXTF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATXUG-01A-01D	NA	PATXUG	NA	NA	NA	01	TARGET	PATXUG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATXWS-01A-01D	NA	PATXWS	NA	NA	NA	01	TARGET	PATXWS_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATXWY-09A-01D	NA	PATXWY	NA	NA	NA	09	TARGET	PATXWY_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATXXF-01A-01D	NA	PATXXF	NA	NA	NA	01	TARGET	PATXXF_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATXXI-01A-01D	NA	PATXXI	NA	NA	NA	01	TARGET	PATXXI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_GPXZ2NQB	NA	PATYAU	NA	25	amplification	01	GMKF	PATYAU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATYCM-01A-01D	NA	PATYCM	NA	NA	NA	01	TARGET	PATYCM_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATYDC-01A-01D	NA	PATYDC	NA	NA	NA	01	TARGET	PATYDC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATYEJ-01A-01D	NA	PATYEJ	NA	NA	NA	01	TARGET	PATYEJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_FSNCPJJF	NA	PATYGV	NA	NA	NA	01	GMKF	PATYGV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
NA	TARGET-30-PATYIL-01A-01R	PATYIL	561.5	NA	NA	01	TARGET	PATYIL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN amplified
NA	TARGET-30-PATYIL-02A-01R	PATYIL	637.82	NA	NA	02	TARGET	PATYIL_02_Solid Tissue_Recurrence	MYCN non-amp	NBL, MYCN amplified
TARGET-30-PATYMK-01A-01D	NA	PATYMK	NA	NA	NA	01	TARGET	PATYMK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATYMS-01A-01D	NA	PATYMS	NA	NA	NA	01	TARGET	PATYMS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATYMZ-01A-01D	NA	PATYMZ	NA	NA	NA	01	TARGET	PATYMZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_QSTNH2MJ	NA	PATYNP	NA	3	gain	01	GMKF	PATYNP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PATYPH-01A-01D	NA	PATYPH	NA	NA	NA	01	TARGET	PATYPH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_PWXXZMSR	NA	PATYRV	NA	NA	NA	01	GMKF	PATYRV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_A3K94FCY	NA	PATYWG	NA	NA	NA	01	GMKF	PATYWG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATYWM-01A-01D	NA	PATYWM	NA	NA	NA	01	TARGET	PATYWM_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PATYWX-01A-01D	NA	PATYWX	NA	NA	NA	01	TARGET	PATYWX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_1HXG4A7B	NA	PATYXS	NA	NA	NA	01	GMKF	PATYXS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATZBH-01A-01D	NA	PATZBH	NA	NA	NA	01	TARGET	PATZBH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PATZIG-01A-01D	NA	PATZIG	NA	NA	NA	01	TARGET	PATZIG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_A527Y2QF	BS_S4WH99C9	PATZRF	235.02	18	amplification	01	GMKF	PATZRF_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATZRF-01A-01D	BS_S4WH99C9	PATZRF	235.02	NA	NA	01	TARGET	PATZRF_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PATZRU-01A-01D	NA	PATZRU	NA	NA	NA	01	TARGET	PATZRU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_0QTY32QA	NA	PATZZJ	NA	3	gain	01	GMKF	PATZZJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_HQC1EKZ8	BS_0JBZPAGN	PAUAEE	31.89	3	loss	01	GMKF	PAUAEE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_A2Z4DDQS	NA	PAUAEK	NA	NA	NA	01	GMKF	PAUAEK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_EWNSDJ7V	NA	PAUAFH	NA	NA	NA	01	GMKF	PAUAFH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_WKPJ7S74	NA	PAUAKC	NA	NA	NA	01	GMKF	PAUAKC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUAKT-01A-01D	NA	PAUAKT	NA	NA	NA	01	TARGET	PAUAKT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_QEKBZRMD	NA	PAUALH	NA	3	loss	01	GMKF	PAUALH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUATG-01A-01D	NA	PAUATG	NA	NA	NA	01	TARGET	PAUATG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_MMCZHZE6	NA	PAUAZA	NA	NA	NA	01	GMKF	PAUAZA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUAZA-01A-01D	NA	PAUAZA	NA	NA	NA	01	TARGET	PAUAZA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_TDV0SYNR	NA	PAUAZW	NA	NA	NA	01	GMKF	PAUAZW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBDC-01A-01D	NA	PAUBDC	NA	NA	NA	01	TARGET	PAUBDC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBEC-01A-01D	NA	PAUBEC	NA	NA	NA	01	TARGET	PAUBEC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBFU-01A-01D	NA	PAUBFU	NA	NA	NA	01	TARGET	PAUBFU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBGW-01A-01D	NA	PAUBGW	NA	NA	NA	01	TARGET	PAUBGW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUBHV-01A-01D	NA	PAUBHV	NA	NA	NA	01	TARGET	PAUBHV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBPW-09A-01D	NA	PAUBPW	NA	NA	NA	09	TARGET	PAUBPW_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBRR-01A-01D	NA	PAUBRR	NA	NA	NA	01	TARGET	PAUBRR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBSW-01A-01D	NA	PAUBSW	NA	NA	NA	01	TARGET	PAUBSW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_M0N8YXTA	NA	PAUBVN	NA	NA	NA	01	GMKF	PAUBVN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBVN-01A-01D	NA	PAUBVN	NA	NA	NA	01	TARGET	PAUBVN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBWP-01A-01D	NA	PAUBWP	NA	NA	NA	01	TARGET	PAUBWP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUBYW-01A-01D	NA	PAUBYW	NA	NA	NA	01	TARGET	PAUBYW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUCFI-01A-01D	NA	PAUCFI	NA	NA	NA	01	TARGET	PAUCFI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUCGP-01A-01D	NA	PAUCGP	NA	NA	NA	01	TARGET	PAUCGP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_FR9R7VFY	BS_YMWFA93F	PAUCIK	12.05	NA	NA	01	GMKF	PAUCIK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUCKF-01A-01D	NA	PAUCKF	NA	NA	NA	01	TARGET	PAUCKF_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_HQYHVPC9	NA	PAUCMD	NA	3	gain	01	GMKF	PAUCMD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_KTHF096D	BS_HEJAPS03	PAUCNL	22.84	NA	NA	01	GMKF	PAUCNL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_PGBR1H2A	BS_SM1QE9FJ	PAUCRL	10.42	NA	NA	01	GMKF	PAUCRL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUCRL-01A-01D	BS_SM1QE9FJ	PAUCRL	10.42	NA	NA	01	TARGET	PAUCRL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_GPNWSW71	NA	PAUCXF	NA	NA	NA	01	GMKF	PAUCXF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_G6ASNYWP	NA	PAUCXG	NA	NA	NA	01	GMKF	PAUCXG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_9YMT5HB4	NA	PAUCYI	NA	NA	NA	01	GMKF	PAUCYI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUDBX-01A-01D	NA	PAUDBX	NA	NA	NA	01	TARGET	PAUDBX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
NA	TARGET-30-PAUDDK-01A-01R	PAUDDK	13.43	NA	NA	01	TARGET	PAUDDK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	TARGET-30-PAUDDK-02A-01R	PAUDDK	41.56	NA	NA	02	TARGET	PAUDDK_02_Solid Tissue_Recurrence	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUDDZ-01A-01D	NA	PAUDDZ	NA	NA	NA	01	TARGET	PAUDDZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_4ZE1R1FW	NA	PAUDEK	NA	3	loss	01	GMKF	PAUDEK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_QXZZY4SJ	NA	PAUDFJ	NA	NA	NA	01	GMKF	PAUDFJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_VCXG53E7	NA	PAUDFR	NA	NA	NA	01	GMKF	PAUDFR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUDFR-01A-01D	NA	PAUDFR	NA	NA	NA	01	TARGET	PAUDFR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUDIK-01A-01D	NA	PAUDIK	NA	NA	NA	01	TARGET	PAUDIK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUDMU-01A-01D	NA	PAUDMU	NA	NA	NA	01	TARGET	PAUDMU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUDPP-01A-01D	NA	PAUDPP	NA	NA	NA	01	TARGET	PAUDPP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUDVA-09A-01D	NA	PAUDVA	NA	NA	NA	09	TARGET	PAUDVA_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
BS_EXDY4JFF	NA	PAUEKP	NA	NA	NA	01	GMKF	PAUEKP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUELT-01A-01D	NA	PAUELT	NA	NA	NA	01	TARGET	PAUELT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_NWCPQC60	NA	PAUEWF	NA	NA	NA	01	GMKF	PAUEWF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_WBZBDN0A	BS_6YYC47K2	PAUEXM	40.38	4	gain	01	GMKF	PAUEXM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUEYW-09A-01D	NA	PAUEYW	NA	NA	NA	09	TARGET	PAUEYW_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUEZU-01A-01D	NA	PAUEZU	NA	NA	NA	01	TARGET	PAUEZU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUFFP-01A-01D	NA	PAUFFP	NA	NA	NA	01	TARGET	PAUFFP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_ZK0GRMB1	BS_FXDGYFBR	PAUFHY	1.54	NA	NA	01	GMKF	PAUFHY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUFIM-01A-01D	NA	PAUFIM	NA	NA	NA	01	TARGET	PAUFIM_01_Solid Tissue_Primary Tumor	NA	NBL, To be classified
BS_S8STY9B1	NA	PAUFIT	NA	NA	NA	09	GMKF	PAUFIT_09_Bone Marrow_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_R2G2TPBV	NA	PAUFKP	NA	NA	NA	01	GMKF	PAUFKP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUFPG-01A-01D	NA	PAUFPG	NA	NA	NA	01	TARGET	PAUFPG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUFSR-01A-01D	NA	PAUFSR	NA	NA	NA	01	TARGET	PAUFSR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_8ZFK0D8Z	NA	PAUFSZ	NA	NA	NA	01	GMKF	PAUFSZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUFUS-01A-01D	NA	PAUFUS	NA	NA	NA	01	TARGET	PAUFUS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUFVW-01A-01D	NA	PAUFVW	NA	NA	NA	01	TARGET	PAUFVW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_8D7YYP13	NA	PAUFYH	NA	NA	NA	01	GMKF	PAUFYH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUGGK-01A-01D	NA	PAUGGK	NA	NA	NA	01	TARGET	PAUGGK_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUGIP-01A-01D	NA	PAUGIP	NA	NA	NA	01	TARGET	PAUGIP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_T5BAS1JN	BS_8MYS5HP4	PAUGJI	266.48	68	amplification	01	GMKF	PAUGJI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUGJI-01A-01D	BS_8MYS5HP4	PAUGJI	266.48	NA	NA	01	TARGET	PAUGJI_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUGNL-01A-01D	NA	PAUGNL	NA	NA	NA	01	TARGET	PAUGNL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUGRP-01A-01D	NA	PAUGRP	NA	NA	NA	01	TARGET	PAUGRP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_1BR81RGD	NA	PAUGVU	NA	NA	NA	01	GMKF	PAUGVU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_NQN1P6QY	BS_J9EH31NM	PAUGVZ	15.43	NA	NA	01	GMKF	PAUGVZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUGVZ-01A-01D	BS_J9EH31NM	PAUGVZ	15.43	NA	NA	01	TARGET	PAUGVZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUGWT-01A-01D	NA	PAUGWT	NA	NA	NA	01	TARGET	PAUGWT_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUGZD-01A-01D	NA	PAUGZD	NA	NA	NA	01	TARGET	PAUGZD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUHBZ-01A-01D	NA	PAUHBZ	NA	NA	NA	01	TARGET	PAUHBZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUHFW-01A-01D	NA	PAUHFW	NA	NA	NA	01	TARGET	PAUHFW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUHHW-01A-01D	NA	PAUHHW	NA	NA	NA	01	TARGET	PAUHHW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUHIK-01A-01D	NA	PAUHIK	NA	NA	NA	01	TARGET	PAUHIK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_8C5QG3GE	NA	PAUHSJ	NA	164	amplification	01	GMKF	PAUHSJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUHSJ-01A-01D	NA	PAUHSJ	NA	NA	NA	01	TARGET	PAUHSJ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_NV9ZB445	BS_VV8GRGZ6	PAUHXD	22.9	NA	NA	01	GMKF	PAUHXD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUHYY-01A-01D	NA	PAUHYY	NA	NA	NA	01	TARGET	PAUHYY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUICI-01A-01D	NA	PAUICI	NA	NA	NA	01	TARGET	PAUICI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_ZQEDB5RA	NA	PAUIDD	NA	NA	NA	01	GMKF	PAUIDD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUIFL-01A-01D	NA	PAUIFL	NA	NA	NA	01	TARGET	PAUIFL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_55AHFCX4	NA	PAUIHH	NA	24	amplification	01	GMKF	PAUIHH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUIHH-01A-01D	NA	PAUIHH	NA	NA	NA	01	TARGET	PAUIHH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_00PH2T1P	BS_P10Y42BX	PAUIJR	13.05	3	gain	01	GMKF	PAUIJR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_Y35YEDFF	NA	PAUILS	NA	NA	NA	01	GMKF	PAUILS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_20HSXMYQ	BS_02X4QTNE	PAUIRD	27.44	NA	NA	01	GMKF	PAUIRD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUITU-01A-01D	NA	PAUITU	NA	NA	NA	01	TARGET	PAUITU_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_QWC51APP	NA	PAUIWS	NA	NA	NA	01	GMKF	PAUIWS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUIWS-01A-01D	NA	PAUIWS	NA	NA	NA	01	TARGET	PAUIWS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_4J8JK335	BS_H4TFY19Z	PAUJEJ	111.17	5	amplification	01	GMKF	PAUJEJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN amplified
TARGET-30-PAUJLH-01A-01D	NA	PAUJLH	NA	NA	NA	01	TARGET	PAUJLH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUJPC-01A-01D	NA	PAUJPC	NA	NA	NA	01	TARGET	PAUJPC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUJRW-01A-01D	BS_ZFJS669M	PAUJRW	352.32	NA	NA	01	TARGET	PAUJRW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_FJP95JXF	BS_ZFJS669M	PAUJRW	352.32	3	gain	01	GMKF	PAUJRW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_5DXK26YF	BS_X3F8NMS4	PAUJTY	14.62	NA	NA	01	GMKF	PAUJTY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUJTY-01A-01D	BS_X3F8NMS4	PAUJTY	14.62	NA	NA	01	TARGET	PAUJTY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUJVX-01A-01D	NA	PAUJVX	NA	NA	NA	01	TARGET	PAUJVX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUKAP-01A-01D	NA	PAUKAP	NA	NA	NA	01	TARGET	PAUKAP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUKAW-01A-01D	NA	PAUKAW	NA	NA	NA	01	TARGET	PAUKAW_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUKIJ-01A-01D	NA	PAUKIJ	NA	NA	NA	01	TARGET	PAUKIJ_01_Solid Tissue_Primary Tumor	NA	NBL, To be classified
BS_2R0QBATZ	BS_94JMQ7MX	PAUKLK	296.15	125	amplification	01	GMKF	PAUKLK_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUKLK-01A-01D	BS_94JMQ7MX	PAUKLK	296.15	NA	NA	01	TARGET	PAUKLK_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUKNU-01A-01D	NA	PAUKNU	NA	NA	NA	01	TARGET	PAUKNU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUKRF-01A-01D	NA	PAUKRF	NA	NA	NA	01	TARGET	PAUKRF_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUKVC-01A-01D	NA	PAUKVC	NA	NA	NA	01	TARGET	PAUKVC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_NV00B2Y5	BS_63ACHY8K	PAUKYI	1.68	NA	NA	01	GMKF	PAUKYI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_B95NMCYN	NA	PAULBY	NA	NA	NA	01	GMKF	PAULBY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_5ACNB1BG	BS_CN3256VE	PAULDT	27.11	3	neutral	01	GMKF	PAULDT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_YV3MJ2BD	BS_K59AGJKW	PAULMT	13.26	NA	NA	01	GMKF	PAULMT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAULMT-01A-01D	BS_K59AGJKW	PAULMT	13.26	NA	NA	01	TARGET	PAULMT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAULNF-01A-01D	NA	PAULNF	NA	NA	NA	01	TARGET	PAULNF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAULVH-01A-01D	NA	PAULVH	NA	NA	NA	01	TARGET	PAULVH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_BTRGQHM4	BS_HHNQ3N2V	PAULZB	23.37	3	gain	01	GMKF	PAULZB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUMBB-01A-01D	NA	PAUMBB	NA	NA	NA	01	TARGET	PAUMBB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_RFEDCJTP	BS_WKVJJF3F	PAUMFN	33.64	3	gain	01	GMKF	PAUMFN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_P0BHM8S1	BS_CCV91DR0	PAUMJN	66.35	59	amplification	01	GMKF	PAUMJN_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUMMZ-01A-01D	NA	PAUMMZ	NA	NA	NA	01	TARGET	PAUMMZ_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUMUC-01A-01D	NA	PAUMUC	NA	NA	NA	01	TARGET	PAUMUC_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUMXC-01A-01D	NA	PAUMXC	NA	NA	NA	01	TARGET	PAUMXC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_SFQWVZ4N	NA	PAUNBM	NA	NA	NA	01	GMKF	PAUNBM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_GZG7GH62	NA	PAUNST	NA	3	gain	01	GMKF	PAUNST_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUNST-01A-01D	NA	PAUNST	NA	NA	NA	01	TARGET	PAUNST_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_9BZBCZHK	BS_VNKT3ZZS	PAUNTY	312.62	NA	NA	01	GMKF	PAUNTY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUNTY-01A-01D	BS_VNKT3ZZS	PAUNTY	312.62	NA	NA	01	TARGET	PAUNTY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUNWR-01A-01D	NA	PAUNWR	NA	NA	NA	01	TARGET	PAUNWR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_E9YW2KHS	BS_VR7XMQZ3	PAUNZM	26.7	3	gain	01	GMKF	PAUNZM_01_Solid Tissue_Primary Tumor	NA	NBL, MYCN non-amplified
TARGET-30-PAUPDY-01A-01D	NA	PAUPDY	NA	NA	NA	01	TARGET	PAUPDY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUPGV-01A-01D	NA	PAUPGV	NA	NA	NA	01	TARGET	PAUPGV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUPIC-01A-01D	NA	PAUPIC	NA	NA	NA	01	TARGET	PAUPIC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_TBSPYEEW	NA	PAUPKS	NA	NA	NA	01	GMKF	PAUPKS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_5QFRPR61	BS_FC37XAZK	PAUPMU	3.07	NA	NA	01	GMKF	PAUPMU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_B5MDTA3Q	NA	PAUPNE	NA	NA	NA	01	GMKF	PAUPNE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_2ABKFT99	BS_QCDCAX7G	PAUPNR	21.78	NA	NA	01	GMKF	PAUPNR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUPRN-01A-01D	NA	PAUPRN	NA	NA	NA	01	TARGET	PAUPRN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_J5C6FMYZ	NA	PAUPSP	NA	3	gain	01	GMKF	PAUPSP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_5BB8J64W	BS_T7MWWC0A	PAUPWN	28.78	3	gain	01	GMKF	PAUPWN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUPWX-01A-01D	NA	PAUPWX	NA	NA	NA	01	TARGET	PAUPWX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAURCG-01A-01D	NA	PAURCG	NA	NA	NA	01	TARGET	PAURCG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_E2EXBFN7	NA	PAURCX	NA	NA	NA	01	GMKF	PAURCX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_X242DJMF	NA	PAURFH	NA	3	gain	01	GMKF	PAURFH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAURGD-01A-01D	NA	PAURGD	NA	NA	NA	01	TARGET	PAURGD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_MMBWD5VD	BS_KF4AR0FG	PAURJG	25.32	NA	NA	01	GMKF	PAURJG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAURPL-01A-01D	NA	PAURPL	NA	NA	NA	01	TARGET	PAURPL_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAURUR-01A-01D	NA	PAURUR	NA	NA	NA	01	TARGET	PAURUR_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAURYJ-01A-01D	NA	PAURYJ	NA	NA	NA	01	TARGET	PAURYJ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAURZH-01A-01D	NA	PAURZH	NA	NA	NA	01	TARGET	PAURZH_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_BJCTR4C8	BS_GB1XPW06	PAUSJB	8.68	NA	NA	01	GMKF	PAUSJB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUSJB-01A-01D	BS_GB1XPW06	PAUSJB	8.68	NA	NA	01	TARGET	PAUSJB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_08127AYS	NA	PAUSUV	NA	NA	NA	01	GMKF	PAUSUV_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUSXH-01A-01D	NA	PAUSXH	NA	NA	NA	01	TARGET	PAUSXH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_42Y9E1Q8	NA	PAUTFB	NA	NA	NA	01	GMKF	PAUTFB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_ZED6T1CT	BS_896YFFGE	PAUTFT	86.79	30	amplification	01	GMKF	PAUTFT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN amplified
TARGET-30-PAUTKJ-09A-01D	NA	PAUTKJ	NA	NA	NA	09	TARGET	PAUTKJ_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUTKP-01A-01D	NA	PAUTKP	NA	NA	NA	01	TARGET	PAUTKP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_MA4DE9P2	NA	PAUTLP	NA	246	amplification	01	GMKF	PAUTLP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
TARGET-30-PAUTLP-01A-01D	NA	PAUTLP	NA	NA	NA	01	TARGET	PAUTLP_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_DHC9SHF6	NA	PAUTRA	NA	3	gain	01	GMKF	PAUTRA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUTVX-01A-01D	NA	PAUTVX	NA	NA	NA	01	TARGET	PAUTVX_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUUGT-01A-01D	NA	PAUUGT	NA	NA	NA	01	TARGET	PAUUGT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUUHD-01A-01D	NA	PAUUHD	NA	NA	NA	01	TARGET	PAUUHD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_56CA6BFQ	NA	PAUUHH	NA	72	amplification	01	GMKF	PAUUHH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
BS_2FPVHEQS	NA	PAUUHY	NA	145	amplification	01	GMKF	PAUUHY_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, MYCN amplified
NA	BS_H9BW7Y9C	PAUUTW	25.81	NA	NA	01	GMKF	PAUUTW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_5CR48ZM7	BS_TGDZ491N	PAUUWG	0.83	NA	NA	01	GMKF	PAUUWG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUUZU-01A-01D	NA	PAUUZU	NA	NA	NA	01	TARGET	PAUUZU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_VE90VKZY	BS_591ZWG14	PAUVML	3.96	NA	NA	01	GMKF	PAUVML_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_M7D3Q30Z	BS_XME1VS17	PAUVPT	9.42	NA	NA	01	GMKF	PAUVPT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_P4C0QJ9K	NA	PAUVTG	NA	NA	NA	01	GMKF	PAUVTG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUVVE-01A-01D	NA	PAUVVE	NA	NA	NA	01	TARGET	PAUVVE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_JTP91S1A	BS_2RFA5NWH	PAUWBU	24.9	3	gain	01	GMKF	PAUWBU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUWDK-01A-01D	NA	PAUWDK	NA	NA	NA	01	TARGET	PAUWDK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUWED-01A-01D	NA	PAUWED	NA	NA	NA	01	TARGET	PAUWED_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUWEV-01A-01D	NA	PAUWEV	NA	NA	NA	01	TARGET	PAUWEV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUWFE-01A-01D	NA	PAUWFE	NA	NA	NA	01	TARGET	PAUWFE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_ZPXVVM8K	BS_NC4PWRVP	PAUWHB	11.54	NA	NA	01	GMKF	PAUWHB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_65F8T6N7	NA	PAUWTC	NA	NA	NA	01	GMKF	PAUWTC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUWXY-01A-01D	NA	PAUWXY	NA	NA	NA	01	TARGET	PAUWXY_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUWYM-01A-01D	NA	PAUWYM	NA	NA	NA	01	TARGET	PAUWYM_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAUXFZ-01A-01D	NA	PAUXFZ	NA	NA	NA	01	TARGET	PAUXFZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_8MJNDM75	BS_MBNSCVMH	PAUXGR	6.93	NA	NA	01	GMKF	PAUXGR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUXIW-09A-01D	NA	PAUXIW	NA	NA	NA	09	TARGET	PAUXIW_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
BS_DAX3YVG0	NA	PAUXPT	NA	NA	NA	01	GMKF	PAUXPT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_WZXHZN97	NA	PAUXSV	NA	3	gain	01	GMKF	PAUXSV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAUXSZ-01A-01D	NA	PAUXSZ	NA	NA	NA	01	TARGET	PAUXSZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUXUP-01A-01D	NA	PAUXUP	NA	NA	NA	01	TARGET	PAUXUP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUYDE-01A-01D	NA	PAUYDE	NA	NA	NA	01	TARGET	PAUYDE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_BVAVPKKN	BS_5Y98E084	PAUYFR	11.97	NA	NA	01	GMKF	PAUYFR_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_CWPHVM94	BS_48YZKWC2	PAUYJS	32.85	4	gain	01	GMKF	PAUYJS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_BBK329W5	NA	PAUYKM	NA	NA	NA	01	GMKF	PAUYKM_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUYXX-01A-01D	NA	PAUYXX	NA	NA	NA	01	TARGET	PAUYXX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUZAE-01A-01D	NA	PAUZAE	NA	NA	NA	01	TARGET	PAUZAE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUZMG-01A-01D	NA	PAUZMG	NA	NA	NA	01	TARGET	PAUZMG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUZRC-01A-01D	NA	PAUZRC	NA	NA	NA	01	TARGET	PAUZRC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUZSB-01A-01D	NA	PAUZSB	NA	NA	NA	01	TARGET	PAUZSB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUZTF-01A-01D	NA	PAUZTF	NA	NA	NA	01	TARGET	PAUZTF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAUZZI-01A-01D	NA	PAUZZI	NA	NA	NA	01	TARGET	PAUZZI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAVABN-01A-01D	NA	PAVABN	NA	NA	NA	01	TARGET	PAVABN_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_RR3T675W	BS_323GG6M7	PAVAEE	21.04	3	loss	01	GMKF	PAVAEE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAVAGS-01A-01D	NA	PAVAGS	NA	NA	NA	01	TARGET	PAVAGS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_CQC29CK5	NA	PAVAHC	NA	3	gain	01	GMKF	PAVAHC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_H0MVFRCE	BS_NZDEF29S	PAVALS	30.63	NA	NA	01	GMKF	PAVALS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAVALS-01A-01D	BS_NZDEF29S	PAVALS	30.63	NA	NA	01	TARGET	PAVALS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAVAYF-01A-01D	NA	PAVAYF	NA	NA	NA	01	TARGET	PAVAYF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_THY6PFYF	NA	PAVBAI	NA	NA	NA	01	GMKF	PAVBAI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_2NPW3A08	BS_PRF6XPXV	PAVBLT	15.15	3	gain	01	GMKF	PAVBLT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_PNF2SHN9	BS_8EG9GQZS	PAVBLZ	26.37	NA	NA	01	GMKF	PAVBLZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAVCGD-01A-01D	NA	PAVCGD	NA	NA	NA	01	TARGET	PAVCGD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAVCHH-01A-01D	NA	PAVCHH	NA	NA	NA	01	TARGET	PAVCHH_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAVCJZ-01A-01D	NA	PAVCJZ	NA	NA	NA	01	TARGET	PAVCJZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAVCKK-01A-01D	NA	PAVCKK	NA	NA	NA	01	TARGET	PAVCKK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAVCLI-01A-01D	NA	PAVCLI	NA	NA	NA	01	TARGET	PAVCLI_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_NX91DYXQ	BS_MEN59ZX5	PAVCLX	45.57	3	loss	01	GMKF	PAVCLX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_Q4PTDFKS	NA	PAVCPT	NA	NA	NA	01	GMKF	PAVCPT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
BS_GZ39V8AK	NA	PAVDAS	NA	NA	NA	01	GMKF	PAVDAS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAVDBS-01A-01D	NA	PAVDBS	NA	NA	NA	01	TARGET	PAVDBS_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_Y3KBY0FY	BS_B2BWSTJV	PAVDFW	0.51	NA	NA	01	GMKF	PAVDFW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
TARGET-30-PAVDGG-01A-01D	NA	PAVDGG	NA	NA	NA	01	TARGET	PAVDGG_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAVDNK-01A-01D	NA	PAVDNK	NA	NA	NA	01	TARGET	PAVDNK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAVDPE-09A-01D	NA	PAVDPE	NA	NA	NA	09	TARGET	PAVDPE_09_Bone Marrow_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAVDYS-01A-01D	NA	PAVDYS	NA	NA	NA	01	TARGET	PAVDYS_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAVEKN-01A-01D	NA	PAVEKN	NA	NA	NA	01	TARGET	PAVEKN_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, To be classified
TARGET-30-PAVETV-01A-01D	NA	PAVETV	NA	NA	NA	01	TARGET	PAVETV_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
TARGET-30-PAVEZM-01A-01D	NA	PAVEZM	NA	NA	NA	01	TARGET	PAVEZM_01_Solid Tissue_Primary Tumor	MYCN amp	NBL, To be classified
BS_0TER803R	BS_ZGKT8MMX	PAVFAP	24.21	3	loss	01	GMKF	PAVFAP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_J6FPW4H0	BS_FJAQ3KAX	PAVFNX	28.13	NA	NA	01	GMKF	PAVFNX_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_6K2SSJ77	NA	PAVFZW	NA	3	gain	09	GMKF	PAVFZW_09_Bone Marrow_Primary Tumor	MYCN amp	Pathology-amp,MYCN_CN_status-non-amp,TPM-NA
BS_JV1GTZ1Q	BS_82Q78622	PAVGYW	32.44	3	gain	01	GMKF	PAVGYW_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_X8H38ZNB	BS_KV05J5BX	PAVHEU	6.12	NA	NA	01	GMKF	PAVHEU_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_MW0JYGG1	BS_6DXDS5EE	PAVHGP	22.71	NA	NA	01	GMKF	PAVHGP_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_0T5A16N2	BS_KHW6ASK4	PAVHWG	17.78	NA	NA	01	GMKF	PAVHWG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_4GHFYCWZ	BS_QM9CBE54	PAVIAZ	1.41	NA	NA	01	GMKF	PAVIAZ_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_7BJQNVK8	BS_EMBK3HHP	PAVINE	19.52	3	gain	01	GMKF	PAVINE_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_GNETMRJF	BS_KG9X0NFD	PAVINT	8.91	3	loss	01	GMKF	PAVINT_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_3KPKZVGX	BS_ZKQXXTG9	PAVIZV	10.07	3	gain	01	GMKF	PAVIZV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_S8Q6R8MX	BS_70H191SN	PAVJEG	5.13	NA	NA	01	GMKF	PAVJEG_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_WBTZK7A2	BS_HBMHZEGZ	PAVJEV	14.22	NA	NA	01	GMKF	PAVJEV_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_59BAHXTQ	NA	PAVJMA	NA	1	loss	01	GMKF	PAVJMA_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_TKRH7YW7	NA	PAVJTD	NA	4	gain	01	GMKF	PAVJTD_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_95PV1RRY	BS_SZ3EJPGV	PAVKRF	12.8	NA	NA	01	GMKF	PAVKRF_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_QWX24M4X	BS_5Y7PNW71	PAVKZC	1.65	NA	NA	01	GMKF	PAVKZC_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_P5VHEN5Q	BS_R232Y3SW	PAVLFB	48.11	NA	NA	01	GMKF	PAVLFB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	BS_YG0W2BBN	PAVMHB	1.03	NA	NA	01	GMKF	PAVMHB_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
BS_87J6X9KJ	BS_135GYQQD	PAVNLK	27.75	NA	NA	01	GMKF	PAVNLK_01_Solid Tissue_Primary Tumor	MYCN non-amp	NBL, MYCN non-amplified
NA	PPTC_VID4Q7JK	PPTC_P0061	62.14	NA	NA	CHLA-79	PPTC	PPTC_P0061_CHLA-79_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN non-amplified
NA	MARIS_EYOIVTPU	PPTC_P0062	812.6	NA	NA	COG-N-415	Maris	PPTC_P0062_COG-N-415_Derived Cell Line_Progressive_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Amplified; ALK F1174L; TP53 WT	NBL, MYCN amplified
NA	PPTC_ATC9QVCW	PPTC_P0062	2349.81	NA	NA	COG-N-415x	PPTC	PPTC_P0062_COG-N-415x_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_LOUMEHPY	PPTC_P0063	865.82	NA	NA	COG-N-421x	PPTC	PPTC_P0063_COG-N-421x_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_WESCL9QP	PPTC_P0064	1095.29	NA	NA	COG-N-424x	PPTC	PPTC_P0064_COG-N-424x_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_GSB8EQG2	PPTC_P0065	6.03	NA	NA	Felix-COG-N-426	Maris	PPTC_P0065_Felix-COG-N-426_Derived Cell Line_Relapse_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Non-amplified; ALK F1245C; TP53 WT	NBL, MYCN non-amplified
NA	PPTC_AZ37GWMQ	PPTC_P0065	65.22	NA	NA	COG-N-426x-Felix-PDX	PPTC	PPTC_P0065_COG-N-426x-Felix-PDX_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN non-amplified
NA	MARIS_Y912NFAI	PPTC_P0066	486.74	NA	NA	COG-N-440	Maris	PPTC_P0066_COG-N-440_Derived Cell Line_Relapse_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Amplified; ALK WT; TP53 WT	NBL, MYCN amplified
NA	PPTC_Z83IPQ2P	PPTC_P0066	1245.53	NA	NA	COG-N-440x	PPTC	PPTC_P0066_COG-N-440x_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_U6GGLN7Q	PPTC_P0067	285.88	NA	NA	COG-N-453	Maris	PPTC_P0067_COG-N-453_Derived Cell Line_Relapse_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Amplified; ALK F1174L; TP53 WT	NBL, MYCN amplified
NA	PPTC_HSR1JTCY	PPTC_P0067	707	NA	NA	COG-N-453x	PPTC	PPTC_P0067_COG-N-453x_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_OKKFERDA	PPTC_P0067	1063.69	NA	NA	COG-N-452x	PPTC	PPTC_P0067_COG-N-452x_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_LIHSF6XQ	PPTC_P0068	340.04	NA	NA	COG-N-471nb	Maris	PPTC_P0068_COG-N-471nb_Derived Cell Line_Relapse_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Amplified; ALK WT; TP53 WT	NBL, MYCN amplified
NA	PPTC_NEVTLBQX	PPTC_P0068	1119.62	NA	NA	COG-N-471x	PPTC	PPTC_P0068_COG-N-471x_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_AMXOJX4R	PPTC_P0069	2223.08	NA	NA	COG-N-480x	PPTC	PPTC_P0069_COG-N-480x_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_U1TN5LPF	PPTC_P0070	177.64	NA	NA	COG-N-496	Maris	PPTC_P0070_COG-N-496_Derived Cell Line_Primary Tumor_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Amplified; ALK Unknown; TP53 Unknown	NBL, MYCN amplified
NA	PPTC_PROQBSZV	PPTC_P0070	653.37	NA	NA	COG-N-496x	PPTC	PPTC_P0070_COG-N-496x_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_GCZQZERV	PPTC_P0071	1250.52	NA	NA	COG-N-519	Maris	PPTC_P0071_COG-N-519_Derived Cell Line_Relapse_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Amplified; ALK Unknown; TP53 Unknown	NBL, MYCN amplified
NA	PPTC_UKKD06QF	PPTC_P0071	2502.45	NA	NA	COG-N-519x	PPTC	PPTC_P0071_COG-N-519x_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_CHISQWZY	PPTC_P0072	16.13	NA	NA	COG-N-549	Maris	PPTC_P0072_COG-N-549_Derived Cell Line_Progressive_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Non-amplified; ALK Unknown; TP53 Unknown	NBL, MYCN non-amplified
NA	PPTC_LQ6Y7A1M	PPTC_P0072	47.69	NA	NA	COG-N-549x	PPTC	PPTC_P0072_COG-N-549x_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN non-amplified
NA	MARIS_ABSRSWVF	PPTC_P0073	271.98	NA	NA	COG-N-557nb	Maris	PPTC_P0073_COG-N-557nb_Derived Cell Line_Primary Tumor_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Amplified; ALK Unknown; TP53 Unknown	NBL, MYCN amplified
NA	PPTC_54DHIOQ8	PPTC_P0073	2177.22	NA	NA	COG-N-557x	PPTC	PPTC_P0073_COG-N-557x_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_8IVKZKFF	PPTC_P0074	1305.88	NA	NA	COG-N-560x	PPTC	PPTC_P0074_COG-N-560x_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_ZJXYU1BK	PPTC_P0075	431.61	NA	NA	COG-N-561	Maris	PPTC_P0075_COG-N-561_Derived Cell Line_Relapse_NA_NA	1p36 del Unknown; 3p26 del Unknown; 11q23 del Unknown; 17q21-qter unbal gain Unknown; MYCN Amplified; ALK Unknown; TP53 Unknown	NBL, MYCN amplified
NA	PPTC_SL7X6FA8	PPTC_P0075	1797.29	NA	NA	COG-N-561x	PPTC	PPTC_P0075_COG-N-561x_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_PA8ZOTZO	PPTC_P0076	723.45	NA	NA	COG-N-564x	PPTC	PPTC_P0076_COG-N-564x_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_QNLYDL7E	PPTC_P0077	41.95	NA	NA	COG-N-589x	PPTC	PPTC_P0077_COG-N-589x_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN non-amplified
NA	PPTC_TPFVVATE	PPTC_P0078	314.31	NA	NA	COG-N-590x	PPTC	PPTC_P0078_COG-N-590x_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_9LVWBU8B	PPTC_P0079	717.56	NA	NA	COG-N-623x	PPTC	PPTC_P0079_COG-N-623x_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_ZVWIYKN9	PPTC_P0079	425.85	NA	NA	COG-N-603x	PPTC	PPTC_P0079_COG-N-603x_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_XI4JM8IG	PPTC_P0080	13.7	NA	NA	COG-N-619x	PPTC	PPTC_P0080_COG-N-619x_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN non-amplified
NA	PPTC_OPN43SQN	PPTC_P0081	51.23	NA	NA	COG-N-620x	PPTC	PPTC_P0081_COG-N-620x_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN non-amplified
NA	PPTC_HDGGBVIL	PPTC_P0082	23.32	NA	NA	COG-N-624x	PPTC	PPTC_P0082_COG-N-624x_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN non-amplified
NA	PPTC_AVD76PB4	PPTC_P0083	48.55	NA	NA	COG-N-625x	PPTC	PPTC_P0083_COG-N-625x_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN non-amplified
NA	PPTC_IW87M9YQ	PPTC_P0165	1241.53	NA	NA	NB-1382	PPTC	PPTC_P0165_NB-1382_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_FHJWCMO7	PPTC_P0166	630.08	NA	NA	NB-1643	Maris	PPTC_P0166_NB-1643_Derived Cell Line_Primary Tumor_NA_NA	1p36 del Loss p34.2-pter; 3p26 del None; 11q23 del Loss q23.1-qter; 17q21-qter unbal gain Gain q21.31-qter; MYCN Amplified; ALK R1275Q; TP53 WT	NBL, MYCN amplified
NA	PPTC_5YRNDC30	PPTC_P0166	1610.93	NA	NA	NB-1643	PPTC	PPTC_P0166_NB-1643_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_UCRJOLAA	PPTC_P0167	152.33	NA	NA	NB-1691	Maris	PPTC_P0167_NB-1691_Derived Cell Line_Progressive_NA_NA	1p36 del None; 3p26 del Loss p26.1; 11q23 del LOH q11-qter, Loss q22.1-q24.3; 17q21-qter unbal gain None?; MYCN Amplified; ALK WT; TP53 WT	NBL, MYCN amplified
NA	PPTC_ZFRSXHVQ	PPTC_P0167	734.7	NA	NA	NB-1691	PPTC	PPTC_P0167_NB-1691_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_AWZ9HDXM	PPTC_P0168	2285.16	NA	NA	NB-1771	PPTC	PPTC_P0168_NB-1771_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN amplified
NA	MARIS_JGAXN9EJ	PPTC_P0169	15.08	NA	NA	NB-EBc1	Maris	PPTC_P0169_NB-EBc1_Derived Cell Line_Progressive_NA_NA	1p36 del Loss p35.2-pter; 3p26 del Gain p26.1-pter; 11q23 del Loss q21-24.2; 17q21-qter unbal gain Gain q21.31-qter; MYCN Non-amplified; ALK WT; TP53 WT	NBL, MYCN non-amplified
NA	PPTC_0OCOQKP9	PPTC_P0169	65.36	NA	NA	NB-EBc1	PPTC	PPTC_P0169_NB-EBc1_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN non-amplified
NA	PPTC_WB6OSRXV	PPTC_P0170	61.14	NA	NA	NB-Fly-623m	PPTC	PPTC_P0170_NB-Fly-623m_Patient Derived Xenograft_Relapse	Neuroblastoma	NBL, MYCN non-amplified
NA	MARIS_9JXQHHNY	PPTC_P0171	650.92	NA	NA	NB-SD	Maris	PPTC_P0171_NB-SD_Derived Cell Line_Progressive_NA_NA	1p36 del Loss p21.3-pter; 3p26 del Loss p13-pter; 11q23 del cnLOH q23.2-23.3; 17q21-qter unbal gain Gain q12-qter; MYCN Amplified; ALK F1174L; TP53 C176F	NBL, MYCN amplified
NA	PPTC_KB5T2UVM	PPTC_P0171	1168.36	NA	NA	NB-SD	PPTC	PPTC_P0171_NB-SD_Patient Derived Xenograft_Progressive	Neuroblastoma	NBL, MYCN amplified
NA	PPTC_WS87CENR	PPTC_P0181	38.85	NA	NA	NCH-NB-1	PPTC	PPTC_P0181_NCH-NB-1_Patient Derived Xenograft_Primary Tumor	Neuroblastoma	NBL, MYCN non-amplified
NA	BS_JHEHJN1M	PT_0Q496N0Q	NA	NA	NA	ET_DVMP5JR3	DGD	PT_0Q496N0Q_ET_DVMP5JR3_Not Available_Primary Tumor	NA	NBL, To be classified
BS_AK1A6MWG	NA	PT_203SE2J7	NA	NA	NA	ET_9KHW93V8	DGD	PT_203SE2J7_ET_9KHW93V8_Not Available_Progressive	NA	NBL, To be classified
NA	BS_PTTZ15MN	PT_203SE2J7	NA	NA	NA	ET_2SFY7T52	DGD	PT_203SE2J7_ET_2SFY7T52_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_WE9Z7PE2	PT_203SE2J7	NA	NA	NA	ET_F2D4F1MQ	DGD	PT_203SE2J7_ET_F2D4F1MQ_Not Available_Progressive	NA	NBL, To be classified
NA	BS_YP080MN8	PT_23G70TEN	NA	NA	NA	ET_6JDFDV10	DGD	PT_23G70TEN_ET_6JDFDV10_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_G0C2BKGC	PT_40VEXGGS	NA	NA	NA	ET_3KTJ1ST0	DGD	PT_40VEXGGS_ET_3KTJ1ST0_Not Available_Primary Tumor	Neuroblastoma of the Adrenal Gland and Sympathetic Nervous System	NBL, To be classified
BS_KP0YNTAK	BS_1RT76ANT	PT_5SX0GRW1	11.88	4	gain	7316-1927	PBTA	PT_5SX0GRW1_7316-1927_Solid Tissue_Deceased	Metastatic secondary tumors;Neuroblastoma	NBL, MYCN non-amplified
BS_76YE7XNX	NA	PT_5ZPPR06P	NA	NA	NA	7316-4214	PBTA	PT_5ZPPR06P_7316-4214_Solid Tissue_Initial CNS Tumor	neuroblastoma	NBL, To be classified
BS_EBW10QNH	NA	PT_5ZPPR06P	NA	NA	NA	7316-6301	PBTA	PT_5ZPPR06P_7316-6301_Solid Tissue_Progressive	ganglioneuroblastoma, intermixed	NBL, To be classified
NA	BS_B9XBBA8D	PT_5ZPPR06P	NA	NA	NA	ET_1QEB44PQ	DGD	PT_5ZPPR06P_ET_1QEB44PQ_Not Available_Progressive	metastatic peripheral neuroblastic tumor	NBL, To be classified
NA	BS_V1Q5A9B1	PT_5ZPPR06P	NA	NA	NA	7316-4214	DGD	PT_5ZPPR06P_7316-4214_Not Available_Initial CNS Tumor	neuroblastoma	NBL, To be classified
NA	BS_0C4V1TW4	PT_75K756RD	NA	NA	NA	ET_DCF188S7	DGD	PT_75K756RD_ET_DCF188S7_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_8EKCJ7EF	PT_75K756RD	NA	NA	NA	ET_B2BM718W	DGD	PT_75K756RD_ET_B2BM718W_Not Available_Recurrence	NA	NBL, To be classified
NA	BS_ZZA88AMB	PT_8KF6YSTW	NA	NA	NA	ET_5K8PDRFC	DGD	PT_8KF6YSTW_ET_5K8PDRFC_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_HEDCVFKC	PT_936J0BZ5	NA	NA	NA	ET_9ZA5FKKS	DGD	PT_936J0BZ5_ET_9ZA5FKKS_Not Available_Progressive	NA	NBL, To be classified
BS_YC4RWPH3	BS_ZJGXGR1V	PT_9F58PWB3	179.59	26	amplification	7316-3960	PBTA	PT_9F58PWB3_7316-3960_Solid Tissue_Progressive	neuroblastoma	NBL, MYCN amplified
BS_RECF1S4Q	BS_H9YYADDT	PT_BCBMG74N	NA	NA	NA	ET_EJ3H8NNB	DGD	PT_BCBMG74N_ET_EJ3H8NNB_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_0Q47HY02	PT_CQ3AXEKK	NA	NA	NA	ET_2AZE66GF	DGD	PT_CQ3AXEKK_ET_2AZE66GF_Not Available_Progressive	NA	NBL, To be classified
BS_VV8Q40Y7	BS_0X4NPYD3	PT_CQ9MX63F	NA	NA	NA	ET_2ZJ7FWEY	DGD	PT_CQ9MX63F_ET_2ZJ7FWEY_Solid Tissue_Recurrence	Recurrent Neuroblastoma	NBL, To be classified
NA	BS_EY0C9N6Z	PT_CQN8M3RF	NA	NA	NA	ET_44GZCX5A	DGD	PT_CQN8M3RF_ET_44GZCX5A_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_RWZRY9CF	PT_D19XT3GV	NA	NA	NA	ET_6JGS3HVH	DGD	PT_D19XT3GV_ET_6JGS3HVH_Not Available_Primary Tumor	Neuroblastoma of the Adrenal Gland and Sympathetic Nervous System	NBL, To be classified
NA	BS_2VFDK3VF	PT_D37GET2Y	NA	NA	NA	ET_7GVE363R	DGD	PT_D37GET2Y_ET_7GVE363R_Not Available_Progressive	NA	NBL, To be classified
NA	BS_CDVX7X1N	PT_D37GET2Y	NA	NA	NA	ET_7ENC4CDH	DGD	PT_D37GET2Y_ET_7ENC4CDH_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_TSNBH5A6	PT_DF18YV38	NA	NA	NA	ET_1CFP6054	DGD	PT_DF18YV38_ET_1CFP6054_Not Available_Primary Tumor	Adrenal Gland Neuroblastoma	NBL, To be classified
BS_4NPEMNAD	BS_DY88N5ZT	PT_DFCZAG9T	93.25	100	amplification	7316-224	PBTA	PT_DFCZAG9T_7316-224_Solid Tissue_Initial CNS Tumor	neuroblastoma, metastatic	NBL, MYCN non-amplified
BS_SR0TJ11R	NA	PT_DHZ5KCNN	NA	NA	NA	7316-7737	PBTA	PT_DHZ5KCNN_7316-7737_Solid Tissue_Recurrence	recurrent ganglioneuroma, schwannian stroma-dominant	NBL, To be classified
BS_F0GNWEJJ	BS_VNWKNRY4	PT_EB0D3BXG	7.83	NA	NA	7316-3311	PBTA	PT_EB0D3BXG_7316-3311_Solid Tissue_Progressive	Metastatic secondary tumors;Neuroblastoma	NBL, MYCN non-amplified
BS_79QMX6KP	NA	PT_EQCQNN1B	NA	NA	NA	7316-9256	PBTA	PT_EQCQNN1B_7316-9256_Solid Tissue_Progressive	neuroblastic tumor, status post chemotherapy, residual	NBL, To be classified
NA	BS_FR7HPS1H	PT_ETJK03VA	NA	NA	NA	ET_A2JE8M6H	DGD	PT_ETJK03VA_ET_A2JE8M6H_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_NNS5GZ7J	PT_FXHEP8CH	NA	NA	NA	ET_98V244ZC	DGD	PT_FXHEP8CH_ET_98V244ZC_Not Available_Primary Tumor	NA	NBL, To be classified
BS_5J5VH3X0	BS_2SHWPB5P	PT_FZHGKJ0H	0.18	NA	NA	7316-4034	PBTA	PT_FZHGKJ0H_7316-4034_Solid Tissue_Initial CNS Tumor	ganglioneuroblastoma, stage ii favorable histology non n-myc amplified	NBL, MYCN non-amplified
BS_NHMPQ8Q1	BS_JBGZ7HHZ	PT_FZHGKJ0H	0.02	NA	NA	7316-4033	PBTA	PT_FZHGKJ0H_7316-4033_Solid Tissue_Initial CNS Tumor	ganglioneuroblastoma, stage ii favorable histology non n-myc amplified	NBL, MYCN non-amplified
BS_RA4GZM25	NA	PT_FZHGKJ0H	NA	NA	NA	7316-4258	PBTA	PT_FZHGKJ0H_7316-4258_Solid Tissue_Progressive	post treatment peripheral neuroblastic tumor	NBL, To be classified
BS_3J9DF2XX	NA	PT_GRZE094W	NA	NA	NA	ET_EWVBBFT6	DGD	PT_GRZE094W_ET_EWVBBFT6_Not Available_Unknown	High Risk Neuroblastoma	NBL, To be classified
NA	BS_29E2B8BX	PT_GRZE094W	NA	NA	NA	ET_AFWA6XC1	DGD	PT_GRZE094W_ET_AFWA6XC1_Not Available_Primary Tumor	High Risk Neuroblastoma	NBL, To be classified
NA	BS_WAH4KKQ5	PT_HGWCJDHV	NA	NA	NA	ET_FFDK4P5W	DGD	PT_HGWCJDHV_ET_FFDK4P5W_Not Available_Progressive	NA	NBL, To be classified
NA	BS_R91DDK9A	PT_HVCRDJ95	NA	NA	NA	ET_AWW0E9A6	DGD	PT_HVCRDJ95_ET_AWW0E9A6_Not Available_Progressive	High Risk Neuroblastoma	NBL, To be classified
NA	BS_9P9DNAHS	PT_J01MB51G	NA	NA	NA	ET_DJ152PHW	DGD	PT_J01MB51G_ET_DJ152PHW_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_JS7G87QP	PT_JPBMNESN	NA	NA	NA	ET_C228BTEJ	DGD	PT_JPBMNESN_ET_C228BTEJ_Not Available_Primary Tumor	Neuroblastoma of the Adrenal Gland and Sympathetic Nervous System	NBL, To be classified
BS_WD253JB2	NA	PT_JPFR0046	NA	NA	NA	ET_4Y4A3Y0P	DGD	PT_JPFR0046_ET_4Y4A3Y0P_Not Available_Recurrence	NA	NBL, To be classified
NA	BS_T88CNJ8A	PT_JPFR0046	NA	NA	NA	ET_AX052MKD	DGD	PT_JPFR0046_ET_AX052MKD_Not Available_Recurrence	Recurrent Neuroblastoma	NBL, To be classified
NA	BS_9NME41F4	PT_JQA14J4Z	NA	NA	NA	ET_39DZBCF4	DGD	PT_JQA14J4Z_ET_39DZBCF4_Not Available_Primary Tumor	NA	NBL, To be classified
BS_YBXM34XV	BS_A05MJ45Y	PT_K0YFKQ6V	NA	NA	NA	7316-7085	DGD	PT_K0YFKQ6V_7316-7085_Not Available_Initial CNS Tumor	peripheral neuroblastic tumor status post-chemotherapy	NBL, To be classified
BS_TJ9KW884	NA	PT_K0YFKQ6V	NA	NA	NA	7316-7085	PBTA	PT_K0YFKQ6V_7316-7085_Solid Tissue_Initial CNS Tumor	peripheral neuroblastic tumor status post-chemotherapy	NBL, To be classified
NA	BS_9Z1VTWJV	PT_K0YFKQ6V	NA	NA	NA	ET_A4K76DSF	DGD	PT_K0YFKQ6V_ET_A4K76DSF_Not Available_Initial CNS Tumor	peripheral neuroblastic tumor status post-chemotherapy	NBL, To be classified
NA	BS_BZXFZKPE	PT_M7B5AK7P	NA	NA	NA	ET_C7H15JCF	DGD	PT_M7B5AK7P_ET_C7H15JCF_Not Available_Progressive	neuroblastoma	NBL, To be classified
NA	BS_TD1ZEQ7R	PT_MRTHX2AQ	3.35	NA	NA	7316-23	PBTA	PT_MRTHX2AQ_7316-23_Solid Tissue_Recurrence	neuroblastoma	NBL, MYCN non-amplified
NA	BS_G1Y281HX	PT_P1290MMP	0.19	NA	NA	7316-125	PBTA	PT_P1290MMP_7316-125_Solid Tissue_Progressive	peripheral neuroblastoma	NBL, MYCN non-amplified
BS_ANFZNMQ4	NA	PT_P6PKT77Y	NA	NA	NA	7316-7741	PBTA	PT_P6PKT77Y_7316-7741_Solid Tissue_Second Malignancy	metastatic neuroblastoma	NBL, To be classified
NA	BS_7DQNG6EM	PT_PE8M2298	NA	NA	NA	ET_9W56H8D9	DGD	PT_PE8M2298_ET_9W56H8D9_Solid Tissue_Primary Tumor	http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C6591	NBL, To be classified
BS_NQ41MEBX	BS_XBQDMMB3	PT_QHJSYTWJ	NA	NA	NA	7316-8120	DGD	PT_QHJSYTWJ_7316-8120_Not Available_Initial CNS Tumor	neuroblastoma (schwannian stroma poor),	NBL, To be classified
BS_NT49M4RG	NA	PT_QHJSYTWJ	NA	NA	NA	7316-8120	PBTA	PT_QHJSYTWJ_7316-8120_Solid Tissue_Initial CNS Tumor	neuroblastoma (schwannian stroma poor),	NBL, To be classified
BS_24TKY0T9	NA	PT_QNHGY3KQ	NA	NA	NA	7316-28	PBTA	PT_QNHGY3KQ_7316-28_Solid Tissue_Recurrence	metastatic neuroblastoma and organizing blood clot	NBL, To be classified
NA	BS_8Y7V5264	PT_RBCEW1B3	NA	NA	NA	ET_4Z0Y8YHR	DGD	PT_RBCEW1B3_ET_4Z0Y8YHR_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_JKR644RJ	PT_RBCEW1B3	NA	NA	NA	ET_5GJA7Q72	DGD	PT_RBCEW1B3_ET_5GJA7Q72_Not Available_Progressive	NA	NBL, To be classified
BS_V13B2K9T	NA	PT_RSVB8R50	NA	NA	NA	ET_6Z42DYPP	DGD	PT_RSVB8R50_ET_6Z42DYPP_Not Available_Primary Tumor	NA	NBL, To be classified
BS_68BZ8N6P	BS_NGAWSN7T	PT_RXT6KRR6	8.48	NA	NA	7316-3168	PBTA	PT_RXT6KRR6_7316-3168_Solid Tissue_Recurrence	ganglioneuroblastoma, who grade iv	NBL, MYCN non-amplified
BS_CK7CPM73	BS_NFRXNAFE	PT_RXT6KRR6	4.68	3	gain	7316-3147	PBTA	PT_RXT6KRR6_7316-3147_Solid Tissue_Recurrence	ganglioneuroblastoma	NBL, MYCN non-amplified
NA	BS_8P02DSEP	PT_TC6A6TX7	NA	NA	NA	ET_4SC6AA4T	DGD	PT_TC6A6TX7_ET_4SC6AA4T_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_327GE38E	PT_TMY5EVG3	NA	NA	NA	ET_0QD356EC	DGD	PT_TMY5EVG3_ET_0QD356EC_Not Available_Primary Tumor	Neuroblastoma of the Adrenal Gland and Sympathetic Nervous System	NBL, To be classified
NA	BS_YTYSPH4Q	PT_TSZV8DK6	NA	NA	NA	ET_FJ2TDG7J	DGD	PT_TSZV8DK6_ET_FJ2TDG7J_Not Available_Primary Tumor	Neuroblastoma of the Adrenal Gland and Sympathetic Nervous System	NBL, To be classified
NA	BS_2HM4AE24	PT_V5PCYAFJ	NA	NA	NA	ET_FD9T78QE	DGD	PT_V5PCYAFJ_ET_FD9T78QE_Not Available_Recurrence	NA	NBL, To be classified
NA	BS_XV40PE3Q	PT_V5PCYAFJ	NA	NA	NA	ET_FD9T78QE	DGD	PT_V5PCYAFJ_ET_FD9T78QE_Not Available_Recurrence	NA	NBL, To be classified
BS_25VZM81R	BS_XBQZYS8G	PT_W7FK539G	425.63	4	gain	7316-76	PBTA	PT_W7FK539G_7316-76_Solid Tissue_Progressive	Metastatic secondary tumors;Neuroblastoma	NBL, MYCN amplified
NA	BS_HP3E8Q9A	PT_WBXV5ZTN	NA	NA	NA	ET_74PMXWSS	DGD	PT_WBXV5ZTN_ET_74PMXWSS_Solid Tissue_Primary Tumor	Olfactory Neuroblastoma	NBL, To be classified
NA	BS_JFFXWZNX	PT_XCA58RC8	NA	NA	NA	ET_CZRV043G	DGD	PT_XCA58RC8_ET_CZRV043G_Not Available_Progressive	Ganglioneuroblastoma, Intermixed	NBL, To be classified
NA	BS_0F11M2BJ	PT_XN1P30ZC	NA	NA	NA	ET_AAGX4CBE	DGD	PT_XN1P30ZC_ET_AAGX4CBE_Not Available_Recurrence	Recurrent Neuroblastoma	NBL, To be classified
NA	BS_EPXNCYBP	PT_XN1P30ZC	NA	NA	NA	ET_9KNRBT5Q	DGD	PT_XN1P30ZC_ET_9KNRBT5Q_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_7KTGJPVN	PT_Y44DNH44	NA	NA	NA	ET_E5CPBMPG	DGD	PT_Y44DNH44_ET_E5CPBMPG_Not Available_Progressive	NA	NBL, To be classified
NA	BS_G91RJ5XW	PT_Y44DNH44	NA	NA	NA	ET_0N820T72	DGD	PT_Y44DNH44_ET_0N820T72_Not Available_Primary Tumor	NA	NBL, To be classified
NA	BS_V8AE965P	PT_Y5YHX20Q	NA	NA	NA	ET_06Q9BSNT	DGD	PT_Y5YHX20Q_ET_06Q9BSNT_Not Available_Primary Tumor	Neuroblastoma of the Adrenal Gland and Sympathetic Nervous System	NBL, To be classified
NA	BS_JH6Z7W0J	PT_YNYR9X1H	NA	NA	NA	ET_9RW90T87	DGD	PT_YNYR9X1H_ET_9RW90T87_Not Available_Primary Tumor	NA	NBL, To be classified
